0001437749-25-035210 | 10-Q | XBRL Viewer

Revenue from Contract with Customer [Text Block]

Note 4. Revenue and accounts receivable

Revenue for the three and nine months ended September 30, 2025 is primarily derived from services rendered to patients for outpatient behavioral health care, interventional psychiatry, and pain management procedures. The Company’s services have no fixed duration and can generally be terminated by the patient or the Company at any time; therefore, each treatment or visit is considered its own stand-alone contract.

The Company disaggregates revenue from contracts with customers by service type and by payor, as management believes this best depicts the nature, amount, timing, and uncertainty of revenue and cash flows.

Revenue by Service Type (in thousands):

	Three Months Ended September 30, 2025		Nine Months Ended September 30, 2025
Procedures income	$	90	$	90
Therapy services		152		152
Total net patient service revenue	$	242	$	242

Revenue by payor (in thousands):

	Three Months Ended September 30, 2025		Nine Months Ended September 30, 2025
Commercial Insurance	$	156	$	156
Medicare		9		9
Self-Pay		77		77
Total net patient service revenue	$	242	$	242

The Company receives payments from the following sources: (i) commercial insurers; (ii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”) and other programs; (iii) state governments under Medicaid and related programs; and (iv) individual patients and clients.

The Company determines the transaction price based on established billing rates reduced by contractual adjustments, discounts, and implicit price concessions, which represent amounts the Company does not expect to collect based on historical experience and other relevant factors. Contractual adjustments and discounts are based on contractual agreements with commercial insurance and Medicare, discount policies, and historical experience. Implicit price concessions are based on historical collection experience. Most of the Company’s services have contracts containing variable considerations, such as contractual adjustments, discounts, and implicit price concessions, which are estimated and reflected as reductions to revenue in the period the services are provided. However, it is unlikely a significant reversal of revenue will occur when the uncertainty is resolved, and therefore, the Company includes the variable consideration in the estimated transaction price. Subsequent changes resulting from a patient’s ability to pay are recorded as credit loss expense, which is included in other operating expenses. For the nine months ended September 30, 2025, current expected credit loss recovery was less than $0.01 million reflecting a net reversal of the allowance for credit losses following the acquisition of Dura.

The Company derives a significant portion of its revenue from Medicare, and other payors that receive discounts from established billing rates. The Medicare regulations and various managed care contracts under which these discounts must be estimated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided. Management estimates the transaction price on a payor specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ from the Company’s estimates.

Accounts Receivable and allowance for credit loss

Accounts Receivable (in thousands):

	September 30, 2025
Accounts receivable, gross	$	349
Less: allowance for credit losses		(110	)
Accounts receivable, net	$	239

Allowance for credit losses roll-forward (in thousands):

Beginning balance as of December 31, 2024	$	-
Acquisition of Dura (September 8, 2025)		113
Provision (recovery) for expected credit losses		(3	)
Write-offs, net of recoveries		-
Ending Balance as of September 30, 2025	$	110

Accounts Receivable by payor (in thousands):

	September 30, 2025
Commercial insurance	$	198
Medicare		34
Self-pay		117
Accounts receivable, gross	$	349

Estimation inputs and credit quality information (summary):

●

Receivables are pooled by payer class and aging; loss rates reflect historical experience updated for current conditions and reasonable‑and‑supportable forecasts with reversion to long‑run averages beyond the forecast horizon. The Company does not suspend recognition of revenue on a “nonaccrual” basis for trade receivables.

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

Note 12 - Equity (Details Textual)																					1 Months Ended		3 Months Ended						5 Months Ended	9 Months Ended		12 Months Ended
Note 12 - Equity (Details Textual)	Sep. 30, 2025 USD ($) $ / shares shares	Aug. 18, 2025 USD ($) $ / shares shares	Aug. 15, 2025 USD ($) $ / shares shares	Jul. 17, 2025 USD ($) $ / shares shares	May 15, 2025 USD ($) $ / shares shares	Mar. 20, 2025 USD ($) $ / shares shares	Jan. 29, 2025 USD ($) $ / shares shares	Jan. 27, 2025 USD ($) $ / shares shares	Jan. 20, 2025 USD ($)	Aug. 28, 2024 USD ($) shares	May 23, 2024 USD ($) $ / shares shares	Apr. 19, 2024 USD ($) shares	Apr. 18, 2024 USD ($) $ / shares shares	Mar. 06, 2024 USD ($)	Mar. 05, 2024 USD ($) shares	Feb. 29, 2024 USD ($) $ / shares shares	Feb. 28, 2024 USD ($) $ / shares shares	Feb. 27, 2024 $ / shares shares	Feb. 07, 2024 USD ($) $ / shares shares	Jan. 02, 2024 USD ($) shares	Mar. 31, 2024 shares	Aug. 31, 2023 USD ($) shares	Sep. 30, 2025 USD ($) $ / shares shares	Jun. 30, 2025 USD ($) shares	Mar. 31, 2025 USD ($) shares	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($) shares	Mar. 31, 2024 USD ($) shares	Jul. 29, 2024 $ / shares shares	Sep. 30, 2025 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) shares	Dec. 31, 2024 USD ($) shares	Apr. 17, 2025 USD ($)	Jan. 28, 2025 USD ($) $ / shares shares	Oct. 10, 2024 USD ($) $ / shares shares	Aug. 14, 2024 USD ($) $ / shares shares	Dec. 31, 2023 shares	Aug. 14, 2023 USD ($)	May 24, 2021 $ / shares shares
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares	$ 0.001																						$ 0.001							$ 0.001
Preferred Stock, Shares Authorized (in shares) \| shares	50,000,000																						50,000,000							50,000,000
Stock Issued During Period, Value, New Issues																							$ 6,213,000
Common Stock, Shares Authorized (in shares) \| shares	500,000,000																						500,000,000							500,000,000		500,000,000
Share Price (in dollars per share) \| $ / shares				$ 3
Proceeds from Issuance of Private Placement																														$ 0	$ 1,027,000
Proceeds from Issuance of Common Stock																														4,751,000	0
Stock Issued During Period, Shares, Issued for Services (in shares) \| shares				150,000						20,000
Stock Issued During Period, Value, Issued for Services				$ 450,000						$ 100,000													$ 451,000	$ 150,000		$ 37,000
Gain (Loss) on Convertible Debt Redemption																							(772,000)			(127,000)				(4,239,000)	(127,000)
Gain (Loss) on Issuance of Common Stock																							(0)			(0)				(730,000)	(0)
Gain (Loss) on Consideration Shares and Warrants																							(0)			(0)				$ (1,277,000)	(0)
Class of Warrant or Right, Exercised During Period (in shares) \| shares																														1,870,962
Warrants Exercised, Noncash																														$ 3,087,000	0
Gain (Loss) on Exercise of Warrants																							$ 5,369,000			(0)				$ 5,369,000	(0)
Class of Warrant or Right, Outstanding (in shares) \| shares	9,447,966																						9,447,966							9,447,966		7,173,766					3,321,499
Adjustments to Additional Paid in Capital, Warrant Issued																									$ 3,255,000
Fair Value Adjustment of Warrants																							$ 4,963,000	8,500,000		(165,000)				$ 8,481,000	$ (174,000)
Stock Issuance to Vendor [Member]
Shares Issued, Price Per Share (in dollars per share) \| $ / shares					$ 2.08
Stock Issued During Period, Shares, Issued for Services (in shares) \| shares					75,000
Stock Issued During Period, Value, Issued for Services					$ 200,000
Estimate of Fair Value Measurement [Member]
Warrants and Rights Outstanding	$ 15,900,000																						$ 15,900,000							$ 15,900,000
Anson First Tranche Notes [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares																																				$ 2.4168
Anson, Third Tranche Notes [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares																																		$ 3.78
Anson Second Tranche Notes [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares																																			1,846,128
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares	$ 1.65																						$ 1.65							$ 1.65					$ 1.7664
February Warrants [Member]
Warrants and Rights Outstanding, Term (Year)																	5 years
Adjustments to Additional Paid in Capital, Warrant Issued																	$ 500,000
February Warrants [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input																	3.59
February Warrants [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input																	3.8
February Warrants [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input																	5
February Warrants [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																	1.781
February Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																	0.0426
February Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																	0
RD Purchase Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares							1,215,278	1,215,278
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares						$ 2.3	$ 2.88	$ 2.88
Warrants and Rights Outstanding, Term (Year)							5 years	5 years
Class of Warrant of Right, Grant Date Fair Value							$ 3,983,000
RD Purchase Agreement [Member] \| Estimate of Fair Value Measurement [Member]
Warrants and Rights Outstanding							$ 3,983,000
RD Purchase Agreement [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input							2.07
RD Purchase Agreement [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input							2.88
RD Purchase Agreement [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input							5
RD Purchase Agreement [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input							1.158
RD Purchase Agreement [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input							0.04
Consideration Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares						303,819
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares						$ 2.88
Class of Warrant or Right, Exercise Price, Percentage of Closing Price								80.00%
Warrants and Rights Outstanding						$ 600,000
Class of Warrant or Right Issued in Period (in shares) \| shares						303,819
Class of Warrant or Right, Outstanding (in shares) \| shares						5
Consideration Warrants [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input						2.07
Consideration Warrants [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input						2.88
Consideration Warrants [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input						5
Consideration Warrants [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input						1.158
Consideration Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input						0.04
Amended Anson Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares) \| shares	1,870,960
Proceeds from Warrant Exercises	$ 3,090,000.00
Warrants Exercised, Noncash	5,370,000
Gain (Loss) on Exercise of Warrants	5,370,000
Warrants Exercised, Subscription Receivable	$ 3,090,000.00																						$ 3,090,000.00							$ 3,090,000.00
Substitute Warrants [Member] \| Neuro Rx [Member]
Foreign Currency Exchange Rate, Remeasurement																																							0.316
Class of Warrant or Right, Outstanding (in shares) \| shares																																							3,792,970
Public Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares	344,886																						344,886							344,886		344,886							345,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares																																							$ 115
Class of Warrant or Right, Exercised During Period (in shares) \| shares																							0				0			0	0
Class of Warrant or Right, Outstanding (in shares) \| shares	3,448,856																						3,448,856							3,448,856		3,448,856							3,450,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) \| shares																																							0.1
Private Placement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares	13,625																						13,625							13,625
Class of Warrant or Right, Outstanding (in shares) \| shares	136,250																						136,250							136,250
February Underwriter Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares																	25,000
Warrants and Rights Outstanding, Term (Year)																	5 years
Adjustments to Additional Paid in Capital, Warrant Issued																	$ 100,000
February Underwriter Warrants [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input																	3.05
February Underwriter Warrants [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input																	3.3
February Underwriter Warrants [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input																	5
February Underwriter Warrants [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																	1.781
February Underwriter Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																	0.0426
February Underwriter Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																	0
Underwriter Overallotment Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares															3,750
Adjustments to Additional Paid in Capital, Warrant Issued												$ 100,000			$ 100,000
Underwriter Overallotment Warrants [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input											3.62	3.04			3.05
Underwriter Overallotment Warrants [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input											3.63	3.63			3.3
Underwriter Overallotment Warrants [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input											5	5			5
Underwriter Overallotment Warrants [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input											1.781	1.781			1.781
Underwriter Overallotment Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input											0.0452	0.0466			0.0412
Underwriter Overallotment Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input											0	0			0
Alvogen and Lotus Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares																			419,598
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares																			$ 4
Warrants and Rights Outstanding, Term (Year)																			3 years
Adjustments to Additional Paid in Capital, Warrant Issued																			$ 1,300,000
Class of Warrant or Right, Beneficial Ownership Limitation																			4.99%
Alvogen and Lotus Warrants [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input																			4.1
Alvogen and Lotus Warrants [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input																			4
Alvogen and Lotus Warrants [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input																			3
Alvogen and Lotus Warrants [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																			1.38
Alvogen and Lotus Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																			0.042
Alvogen and Lotus Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																			0
Anson Warrants Tranche One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares																																				1,349,305
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares																																				$ 2.4168
Warrants and Rights Outstanding, Term (Year)																																				5 years
Warrants and Rights Outstanding																																				$ 2,100,000
Anson Warrants Tranche One [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input																																				1.86
Anson Warrants Tranche One [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input																																				2.42
Anson Warrants Tranche One [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input																																				5
Anson Warrants Tranche One [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																																				1.22
Anson Warrants Tranche One [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																																				0.0367
Anson Warrants Tranche One [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																																				0
Anson Warrants Tranche Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares																																			1,846,128
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares																																			$ 1.7664
Warrants and Rights Outstanding, Term (Year)																																			5 years
Warrants and Rights Outstanding																																			$ 1,900,000
Anson Warrants Tranche Two [Member] \| Estimate of Fair Value Measurement [Member]
Warrants and Rights Outstanding																																			$ 1,900,000
Anson Warrants Tranche Two [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input																																			1.38
Anson Warrants Tranche Two [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input																																			1.76
Anson Warrants Tranche Two [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input																																			5
Anson Warrants Tranche Two [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																																			105
Anson Warrants Tranche Two [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																																			3.91
Anson Warrants Tranche Two [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																																			0
Anson Warrants, Tranche Three [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares																																		862,699
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares																																		$ 3.78
Warrants and Rights Outstanding, Term (Year)																																		5 years
Warrants and Rights Outstanding																																		$ 2,500,000
Anson Warrants, Tranche Three [Member] \| Estimate of Fair Value Measurement [Member]
Warrants and Rights Outstanding																																		$ 2,500,000
Anson Warrants, Tranche Three [Member] \| Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input																																		3.55
Anson Warrants, Tranche Three [Member] \| Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input																																		3.78
Anson Warrants, Tranche Three [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input																																		5
Anson Warrants, Tranche Three [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																																		1.13
Anson Warrants, Tranche Three [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																																		0.0433
Anson Warrants, Tranche Three [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																																		0
Anson Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares	1,870,960																						1,870,960							1,870,960
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 1,870,960																						$ 1,870,960							$ 1,870,960
Warrants and Rights Outstanding																																				$ 2,100,000
Proceeds from Warrant Exercises	$ 3,090,000.00
Class of Warrant or Right, Increase (Decrease) in Number of Securities Called by Warrants or Rights (in shares) \| shares	1,870,960
Fair Value Adjustment of Warrants																														$ 5,400,000
Minimum [Member] \| Anson First Tranche Notes [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares																																				$ 0.38
Maximum [Member] \| Alvogen and Lotus Warrants [Member]
Class of Warrant or Right, Beneficial Ownership Limitation																			9.99%
ATM Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares) \| shares																							1,350,788						385,515	1,749,866
Stock Issued During Period, Value, New Issues																							$ 3,740,000	$ 1,012,000		$ 219,000	$ 1,228,000	$ 179,000		$ 4,700,000
Equity Offering, Maximum Offering Amount																																	$ 20,000,000					$ 4,900,000
Payments of Stock Issuance Costs																							100,000							100,000
Proceeds from Issuance or Sale of Equity																							$ 3,810,000							4,850,000
ATM Offering [Member] \| Minimum [Member]
Shares Issued, Price Per Share (in dollars per share) \| $ / shares																													$ 2.42
ATM Offering [Member] \| Maximum [Member]
Shares Issued, Price Per Share (in dollars per share) \| $ / shares																													$ 7.1
February Underwriting Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares) \| shares																		500,000
Shares Issued, Price Per Share (in dollars per share) \| $ / shares																		$ 2.76
Payments of Stock Issuance Costs																	$ 400,000
Share Price (in dollars per share) \| $ / shares																		$ 3
Proceeds from Issuance or Sale of Equity																	$ 1,300,000
February Overallotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares) \| shares																		75,000
Payments of Stock Issuance Costs														$ 200,000
Share Price (in dollars per share) \| $ / shares																		$ 3
Proceeds from Issuance or Sale of Equity														$ 200,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares) \| shares																270,000	270,000
Stock Issued During Period, Value, New Issues																												$ 1,027,000
Private Placement, Premium Percentage																26.70%
Proceeds from Issuance of Private Placement																$ 1,000,000
Private Placement [Member] \| February Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares																270,000	270,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares																$ 3.8	$ 3.8
April Underwriter Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares) \| shares													607,000
Shares Issued, Price Per Share (in dollars per share) \| $ / shares													$ 3.3
April Overallotment Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares) \| shares											91,050		91,050
Shares Issued, Price Per Share (in dollars per share) \| $ / shares											$ 3.3
Payments of Stock Issuance Costs											$ 100,000
Proceeds from Issuance or Sale of Equity											$ 200,000
April 2024 Offering [Member]
Payments of Stock Issuance Costs													$ 400,000
Proceeds from Issuance of Common Stock													$ 1,600,000
April 2024 Offering [Member] \| April Underwriter Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares											4,553	30,350
Warrants and Rights Outstanding, Term (Year)												6 years
April 2024 Offering [Member] \| April Overallotment Warrants [Member]
Warrants and Rights Outstanding, Term (Year)												5 years
RD Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares) \| shares		3,959,999						1,215,278
Stock Issued During Period, Value, New Issues		$ 6,200,000						$ 3,255,000
Shares Issued, Price Per Share (in dollars per share) \| $ / shares		$ 1.65						$ 2.88
Payments of Stock Issuance Costs		$ 300,000						$ 200,000
Proceeds from Issuance or Sale of Equity							$ 3,255,000	$ 3,500,000
Gain (Loss) on Issuance of Common Stock							$ 700,000																							(700,000)
Consent and Waiver Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares) \| shares						303,819
Gain (Loss) on Consideration Shares and Warrants																														(1,280,000)
Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares) \| shares			3,959,999
Stock Issued During Period, Value, New Issues																									$ 3,255,000
Shares Issued, Price Per Share (in dollars per share) \| $ / shares			$ 1.65
Payments of Stock Issuance Costs			$ 300,000
Proceeds from Issuance or Sale of Equity			$ 6,200,000
Conversion of Debt to Common Stock [Member] \| Convertible Debt [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) \| shares																				143,648
Debt Conversion, Converted Instrument, Amount																				$ 400,000
Conversion of Principal and Interest Into Common Stock [Member]
Debt Conversion, Converted Instrument, Amount																														$ 11,142,000	$ 1,102,000
Conversion of Principal and Interest Into Common Stock [Member] \| Anson Convertible Notes [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) \| shares																																3,676,796
Debt Conversion, Converted Instrument, Amount																																$ 5,500,000
Debt Conversion, Original Debt, Amount																																4,200,000
Gain (Loss) on Convertible Debt Redemption																																$ (1,300,000)
Conversion of Principal and Interest Into Common Stock [Member] \| Third Tranche Notes [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) \| shares						5,463
Debt Conversion, Original Debt, Amount						$ 100,000
Conversion of Principal and Interest Into Common Stock [Member] \| Anson First Tranche Notes [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) \| shares																									1,004,055							3,676,796
Debt Conversion, Converted Instrument, Amount																									$ 2,900,000
Debt Conversion, Original Debt, Amount																									1,300,000							$ 4,200,000
Gain (Loss) on Convertible Debt Redemption																									$ (1,600,000)							$ (1,300,000)
Conversion of Principal and Interest Into Common Stock [Member] \| Anson, Third Tranche Notes [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) \| shares						5,463																	877,193	1,879,406	5,463
Debt Conversion, Converted Instrument, Amount																							$ 2,200,000	$ 6,000,000	$ 100,000
Debt Conversion, Original Debt, Amount						$ 100,000			$ 100,000														1,400,000	4,100,000
Gain (Loss) on Convertible Debt Redemption																							$ (800,000)	$ (1,900,000)
Conversion of Principal and Interest Into Common Stock [Member] \| Maximum [Member] \| Anson, Third Tranche Notes [Member]
Debt Conversion, Original Debt, Amount																									100,000
Gain (Loss) on Convertible Debt Redemption																									$ (100,000)
Conversion of Principal and Interest into Consideration Shares [Member] \| Third Tranche Notes [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) \| shares						303,819
Conversion of Principal and Interest into Consideration Warrants [Member] \| Third Tranche Notes [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) \| shares						303,819
Conversion of Series A Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares) \| shares																												3,000,000
Conversion of Stock, Shares Issued (in shares) \| shares																					300,000
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares) \| shares	12,000,000																						12,000,000							12,000,000
Stock Issued During Period, Shares, New Issues (in shares) \| shares																						3
Stock Issued During Period, Value, New Issues																						$ 1,200,000
Preferred Stock, Shares Issued (in shares) \| shares	0																						0							0
Preferred Stock, Shares Outstanding (in shares) \| shares																								0

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2025	Nov. 13, 2025
Document Information [Line Items]
Entity Central Index Key	0001719406
Entity Registrant Name	NRX Pharmaceuticals, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2025
Document Transition Report	false
Entity File Number	001-38302
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-2844431
Entity Address, Address Line One	1201 Orange Street, Suite 600
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19801
City Area Code	484
Local Phone Number	254-6134
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		28,097,627
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase Common Stock
Trading Symbol	NRXPW
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	NRXP
Security Exchange Name	NASDAQ

Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Cash, Uninsured Amount	$ 6,900		$ 6,900
Off-Balance-Sheet, Credit Loss, Liability	0		0
Accounts Receivable, Allowance for Credit Loss	110		110		$ 0
Provision (Reversal) for Doubtful Accounts	100		100
Goodwill, Impairment Loss	0	$ 0	0	$ 0
Asset Impairment Charges	$ 0	$ 0	$ 0	$ 0
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years		5 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years		7 years
Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	7 years		7 years
Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	10 years		10 years
Noncompete Agreements [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	5 years		5 years

Note 11 - Commitments and Contingencies - Schedule of Milestone Payments (Details) - Sarah Herzog Memorial Hospital License Agreement [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Milestone payment	$ 0	$ 0	$ 200,000	$ 0
End of Phase I Clinical Trials of Licensed Product [Member]
Milestone payment			100,000
End of Phase II Clinical Trials of Licensed Product [Member]
Milestone payment			250,000
End of Phase III Clinical Trials of Licensed Product [Member]
Milestone payment			250,000
First Commercial Sale of Licensed Product in U.S. [Member]
Milestone payment			500,000
First Commercial Sale of Licensed Product in Europe [Member]
Milestone payment			500,000
Annual Revenue Threshold [Member]
Milestone payment			$ 750,000

Note 14 - Fair Value Measurements (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2025 USD ($)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net	$ 0

Note 2 - Going Concern (Details Textual) - USD ($)							1 Months Ended	3 Months Ended						5 Months Ended	9 Months Ended
Note 2 - Going Concern (Details Textual) - USD ($)	Oct. 02, 2025	Oct. 01, 2025	Sep. 30, 2025	Aug. 18, 2025	Jan. 29, 2025	Jan. 27, 2025	Nov. 12, 2025	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Jul. 29, 2024	Sep. 30, 2025	Sep. 30, 2024	Apr. 17, 2025	Jan. 28, 2025	Dec. 31, 2024	Aug. 14, 2024	Aug. 14, 2023
Net Income (Loss) Attributable to Parent								$ (5,890,000)	$ (17,581,000)	$ (5,512,000)	$ (1,623,000)	$ (7,897,000)	$ (6,528,000)		$ (28,982,000)	$ (16,048,000)
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation															(10,399,000)	(8,539,000)
Retained Earnings (Accumulated Deficit)			$ (307,256,000)					(307,256,000)							(307,256,000)				$ (278,273,000)
Cash and Cash Equivalent			7,184,000					7,184,000							7,184,000				1,443,000
Working Capital (Deficit)			(28,600,000)					(28,600,000)							(28,600,000)
Revenue from Contract with Customer, Excluding Assessed Tax								242,000			0				242,000	$ 0
Stock Issued During Period, Value, New Issues								6,213,000
Subscription Receivable, Current			$ 3,087,000					$ 3,087,000							$ 3,087,000				$ 0
Third Tranche Notes [Member]
Debt Instrument, Face Amount																		$ 5,400,000
Debt Instrument, Original Issuance Discount																		8.00%
Debt Instrument, Unamortized Discount																		$ 435,000
Debt Issuance Costs, Gross																		400,000
Long-Term Debt, Gross																		$ 5,000,000
First RD Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					1,215,278
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 2.88
Third Tranche Notes, Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																		862,699		862,699,000,000
Anson Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,870,960					1,870,960							1,870,960
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 1,870,960					$ 1,870,960							$ 1,870,960
Proceeds from Warrant Exercises			$ 3,090,000.00
Subscription Receivable, Current			$ 3,090,000.00					$ 3,090,000.00							$ 3,090,000.00
Anson Warrants [Member] \| Subsequent Event [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		1,870,960
Proceeds from Warrant Exercises	$ 3,090,000.00	$ 3,090,000.00
RD Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)				3,959,999		1,215,278
Shares Issued, Price Per Share (in dollars per share)				$ 1.65		$ 2.88
Stock Issued During Period, Value, New Issues				$ 6,200,000		$ 3,255,000
Payments of Stock Issuance Costs				$ 300,000		200,000
Proceeds from Issuance or Sale of Equity					$ 3,255,000	$ 3,500,000
ATM Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)								1,350,788						385,515	1,749,866
Stock Issued During Period, Value, New Issues								$ 3,740,000	$ 1,012,000		$ 219,000	$ 1,228,000	$ 179,000		$ 4,700,000
Payments of Stock Issuance Costs								100,000							100,000
Equity Offering, Maximum Offering Amount																	$ 20,000,000				$ 4,900,000
Proceeds from Issuance or Sale of Equity								$ 3,810,000							$ 4,850,000
ATM Offering [Member] \| Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)							415,097
Payments of Stock Issuance Costs							$ 30,000.00

Note 14 - Fair Value Measurements - Schedule of Significant Inputs (Details)	Sep. 30, 2025 $ / shares	Dec. 31, 2024 $ / shares
Measurement Input, Royalty Rate [Member] \| Trade Names [Member] \| Relief From Royalty Method [Member]
Intangible assets, measurement input	0.05
Measurement Input, Royalty Rate [Member] \| Customer Lists [Member] \| Multi Period Excess Earnings Method (MPEEM) [Member]
Intangible assets, measurement input	0.05
Measurement Input, Revenue Growth Rate Through FY 20230 [Member] \| Trade Names [Member] \| Relief From Royalty Method [Member]
Intangible assets, measurement input	0.10
Measurement Input, Revenue Growth Rate Through FY 20230 [Member] \| Customer Lists [Member] \| Multi Period Excess Earnings Method (MPEEM) [Member]
Intangible assets, measurement input	0.10
Measurement Input, Revenue Growth Rate After FY 2030 [Member] \| Trade Names [Member] \| Relief From Royalty Method [Member]
Intangible assets, measurement input	0.08
Measurement Input, Revenue Growth Rate After FY 2030 [Member] \| Customer Lists [Member] \| Multi Period Excess Earnings Method (MPEEM) [Member]
Intangible assets, measurement input	0.08
Measurement Input, Discount Rate [Member] \| Trade Names [Member] \| Relief From Royalty Method [Member]
Intangible assets, measurement input	0.25
Measurement Input, Discount Rate [Member] \| Customer Lists [Member] \| Multi Period Excess Earnings Method (MPEEM) [Member]
Intangible assets, measurement input	0.27
Measurement Input, Income Tax Rate [Member] \| Trade Names [Member] \| Relief From Royalty Method [Member]
Intangible assets, measurement input	0.265
Measurement Input, Income Tax Rate [Member] \| Customer Lists [Member] \| Multi Period Excess Earnings Method (MPEEM) [Member]
Intangible assets, measurement input	0.265
Measurement Input, Tax Amortization Period [Member] \| Trade Names [Member] \| Relief From Royalty Method [Member]
Intangible assets, measurement input	8
Measurement Input, Tax Amortization Period [Member] \| Customer Lists [Member] \| Multi Period Excess Earnings Method (MPEEM) [Member]
Intangible assets, measurement input	3
Measurement Input, Contributory Assets Charge [Member] \| Customer Lists [Member] \| Multi Period Excess Earnings Method (MPEEM) [Member] \| Minimum [Member]
Intangible assets, measurement input	0.002
Measurement Input, Contributory Assets Charge [Member] \| Customer Lists [Member] \| Multi Period Excess Earnings Method (MPEEM) [Member] \| Maximum [Member]
Intangible assets, measurement input	0.007
Measurement Input, Contributory Assets Charge [Member] \| Noncompete Agreements [Member] \| With and Without Method [Member]
Intangible assets, measurement input	0.40
Measurement Input, Obsolesce [Member] \| Customer Lists [Member] \| Multi Period Excess Earnings Method (MPEEM) [Member]
Intangible assets, measurement input	4
Measurement Input, Distributor EBIT Margin [Member] \| Customer Lists [Member] \| Multi Period Excess Earnings Method (MPEEM) [Member]
Intangible assets, measurement input	0.04
Measurement Input, Replacement Cost Growth Rate [Member] \| Noncompete Agreements [Member] \| With and Without Method [Member]
Intangible assets, measurement input	0.03
Measurement Input, Cap Rate [Member] \| Noncompete Agreements [Member] \| With and Without Method [Member]
Intangible assets, measurement input	0.01
Measurement Input, After Tax Rate of Return [Member] \| Noncompete Agreements [Member] \| With and Without Method [Member]
Intangible assets, measurement input	0.40
Measurement Input, Useful Life [Member] \| Noncompete Agreements [Member] \| With and Without Method [Member]
Intangible assets, measurement input	7
Warrants [Member]
Fair value of warrants (in dollars per share)		$ 1.76
Warrants [Member] \| Minimum [Member]
Fair value of warrants (in dollars per share)	$ 0.02
Warrants [Member] \| Maximum [Member]
Fair value of warrants (in dollars per share)	$ 2.89
Warrants [Member] \| Measurement Input, Share Price [Member]
Warrant measurement input	3.3	2.2
Warrants [Member] \| Measurement Input, Exercise Price [Member]
Warrant measurement input		2.08
Warrants [Member] \| Measurement Input, Exercise Price [Member] \| Minimum [Member]
Warrant measurement input	1.65
Warrants [Member] \| Measurement Input, Exercise Price [Member] \| Maximum [Member]
Warrant measurement input	11.5
Warrants [Member] \| Measurement Input, Expected Term [Member]
Warrant measurement input		4.69
Warrants [Member] \| Measurement Input, Expected Term [Member] \| Minimum [Member]
Warrant measurement input	0.9
Warrants [Member] \| Measurement Input, Expected Term [Member] \| Maximum [Member]
Warrant measurement input	4.33
Warrants [Member] \| Measurement Input, Price Volatility [Member]
Warrant measurement input	1.2431	1.11
Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrant measurement input		0.0437
Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member] \| Minimum [Member]
Warrant measurement input	0.0361
Warrants [Member] \| Measurement Input, Risk Free Interest Rate [Member] \| Maximum [Member]
Warrant measurement input	0.0368
Warrants [Member] \| Measurement Input, Expected Dividend Rate [Member]
Warrant measurement input	0	0
Anson Convertible Notes [Member] \| Measurement Input, Conversion Price [Member]
Measurement input	1.65
Anson Convertible Notes [Member] \| Measurement Input, Expected Term [Member] \| Minimum [Member]
Measurement input	0.5
Anson Convertible Notes [Member] \| Measurement Input, Price Volatility [Member] \| Minimum [Member]
Measurement input	0.712

Note 6 - Furniture and Equipment, Net

9 Months Ended

Sep. 30, 2025

Property, Plant and Equipment Disclosure [Text Block]

Note 6. Furniture and equipment, net

As of September 30, 2025, furniture and equipment, net, consisted of the following (in thousands):

	September 30,			December 31,
	2025			2024
Medical equipment	$	57		$	-
Computer equipment		32			29
Furniture and fixtures		4			-
Total furniture and equipment		93			29
Less: accumulated depreciation		(24	)		(20	)
Furniture and equipment, net	$	69		$	9

Depreciation expense was $2,000 and $4,000 for the three and nine months ended September 30, 2025, respectively. Depreciation expense was $0 and $1,000 for the three and nine months ended September 30, 2024, respectively.

Note 16 - Income Taxes (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Income Tax Expense (Benefit)	$ 0	$ 0

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Note 9 - Alvogen Licensing Agreement

9 Months Ended

Sep. 30, 2025

Collaborative Arrangement Disclosure [Text Block]

Note 9. Alvogen Licensing Agreement

In June 2023, the Company entered into a License Agreement with Alvogen. On June 21, 2024, the Company received a notice of termination from Alvogen effective immediately. Following the termination of the License Agreement by Alvogen, the amounts advanced pursuant to the amendment became due and payable to Alvogen. Accordingly, the refund liability has not been reclassified to deferred revenue or recorded as revenue as of September 30, 2025 and will remain permanent as refund liability until settled.

Upon termination of the License Agreement, the intellectual property rights licensed to Alvogen under the License Agreement reverted to the Company, and all other rights and obligations of each of the parties immediately ceased, except for outstanding amounts owed as of the time of such expiration or termination. As of September 30, 2025, the refund liability due to Alvogen was $4.7 million, which represents all payments made by Alvogen through September 30, 2025, and is included as a component of accrued expense and other current liabilities on the condensed consolidated balance sheet (See Note 8). Following the early termination by Alvogen, the Company does not anticipate recognizing any revenue under the License Agreement. Additionally, in June 2024 the Company wrote off the unfunded stock subscription receivable of $1.3 million related to the warrants previously classified in additional paid-in capital to research and development expense following the termination.

Note 3 - Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2025

Significant Accounting Policies [Text Block]

Note 3. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

Use of Estimates

Certain Risks and Uncertainties

Fair Value of Financial Instruments

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Business Acquisition

Concentration of Credit Risk and Off-Balance Sheet Risk

Cash and Cash Equivalents

Allowance for credit losses

Intangible Assets

Goodwill

Furniture and Equipment, net

Furniture and equipment, net is stated at cost less accumulated depreciation. These assets are depreciated over their estimated useful lives of five to seven years using the straight-line method.

Revenue Recognition

	i.	identify the contract(s) with a customer;
	ii.	identify the performance obligations in the contract;
	iii.	determine the transaction price;
	iv.	allocate the transaction price to the performance obligations within the contract; and
	v.	recognize revenue when (or as) the entity satisfies a performance obligation.

The Company’s revenue arrangements may include the following:

Cost of Patient Services

Research and Development Costs

Non-cancellable Contracts

The Company may record certain obligations as liabilities related to non-cancellable contracts. If appropriate, the offsetting costs may be recorded as a deferred cost asset.

Convertible Notes Payable and Fair Value Election

Stock-Based Compensation

Warrants

Preferred Stock

Segment Information

Income Taxes

Loss Per Share

	September 30,
	2025		2024
Stock options		119,281		131,833
Restricted stock awards		—		33,333
Common Stock warrants		9,447,966		5,327,636
Common Stock issuable upon conversion of Anson Notes		2,127,880		3,236,280
Totals		11,695,127		8,729,082

Recent Accounting Pronouncements Not Yet Adopted

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date.

Note 16 - Income Taxes

9 Months Ended

Sep. 30, 2025

Income Tax Disclosure [Text Block]

Note 16. Income Taxes

The Company recorded no provision or benefit for income tax expense for the nine months ended September 30, 2025 and 2024, respectively.

For all periods presented, the pretax losses incurred by the Company received no corresponding tax benefit because the Company concluded that it is more likely than not that the Company will be unable to realize the value of any resulting deferred tax assets. The Company will continue to assess its position in future periods to determine if it is appropriate to reduce a portion of its valuation allowance in the future.

The entire disclosure for income tax.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

Note 8 - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Refund liability (see Note 9)	$ 4,715	$ 4,715
Professional services	3,949	3,732
Employee costs	420	577
Accrued research and development expense	502	655
Accrued Dura acquisition cost due post-closing	191	0
Other accrued expense	98	470
Total accrued and other current liabilities	$ 9,875	$ 10,149

Note 15 - Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2025

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]

							For the three months
							ended
							September 30,
	NRx			Dura			2025			2024
Expense Category
Income (loss) from operations	$	(4,039	)	$	15		$	(4,024	)	$	(3,022	)
Interest income		(1	)		(1	)		(2	)		(6	)
Interest expense		—			—			—			—
Change in fair value of convertible notes payable		1,502			—			1,502			(1,355	)
Change in fair value of warrant liabilities		4,963			—			4,963			(165	)
Loss on convertible note conversions		772			—			772			127
Gain on exercise of warrants		(5,369	)		—			(5,369	)		—
Net loss	$	(5,906	)	$	16		$	(5,890	)	$	(1,623	)

							For the nine months
							ended
							September 30,
	NRx			Dura			2025			2024
Expense Category
(Loss) income from operations	$	(11,616	)	$	15		$	(11,600	)	$	(16,070	)
Interest income		(7	)		(1	)		(8	)		(40	)
Interest expense		—			—			—			230
Change in fair value of convertible notes payable		8,032			—			8,302			(1,014	)
Change in fair value of warrant liabilities		8,481			—			8,481			(174	)
Loss on issuance of Registered Direct Offering		730			—			730			—
Loss on Consideration Shares and Warrants		1,277			—			1,277			—
Convertible note default penalty		—			—			—			849
Loss on convertible note conversions		4,239			—			4,239			127
Gain on exercise of warrants		(5,369	)		—			(5,369	)		—
Net loss	$	(28,999	)	$	16		$	(28,982	)	$	(16,048	)

Reconciliation of Assets from Segment to Consolidated [Table Text Block]

	NRx			Dura			September 30, 2025			December 31, 2024
Medical equipment	$	—		$	57		$	57		$	—
Computer equipment		29			4			33			29
Furniture and fixtures		—			4			4			—
Total PPE	$	29		$	64		$	93		$	29
Less: Accumulated Depreciation		(23	)		(1	)		(24	)		(19	)
Net	$	6		$	63		$	69		$	9

Note 13 - Stock-based Compensation - Schedule of Restricted Stock Awards (Details) - Restricted Stock [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2025	Dec. 31, 2024	Dec. 31, 2023
Balance (unvested) (in shares)	0	124,166
Unvested, weighted average grant date fair value (in dollars per share)	$ 0	$ 0	$ 5.2
Granted (in shares)	0	0
Vested (in shares)	0	(90,833)
Vested, weighted average grant date fair value (in dollars per share)	$ 0	$ 4.64
Forfeited (in shares)	0	(33,333)
Forfeited, weighted average grant date fair value (in dollars per share)	$ 0	$ 5.2
Balance (unvested) (in shares)	0	0

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	ATM Offering [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	ATM Offering [Member] Common Stock [Member] Series A Preferred Stock [Member]	ATM Offering [Member] Common Stock [Member]	ATM Offering [Member] Additional Paid-in Capital [Member]	ATM Offering [Member] Retained Earnings [Member]	ATM Offering [Member] AOCI Attributable to Parent [Member]	ATM Offering [Member]	Registered Direct Offering [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Registered Direct Offering [Member] Common Stock [Member] Series A Preferred Stock [Member]	Registered Direct Offering [Member] Common Stock [Member]	Registered Direct Offering [Member] Additional Paid-in Capital [Member]	Registered Direct Offering [Member] Retained Earnings [Member]	Registered Direct Offering [Member] AOCI Attributable to Parent [Member]	Registered Direct Offering [Member]	Common Stock and Warrant Issuance [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock and Warrant Issuance [Member] Common Stock [Member] Series A Preferred Stock [Member]	Common Stock and Warrant Issuance [Member] Common Stock [Member]	Common Stock and Warrant Issuance [Member] Additional Paid-in Capital [Member]	Common Stock and Warrant Issuance [Member] Retained Earnings [Member]	Common Stock and Warrant Issuance [Member] AOCI Attributable to Parent [Member]	Common Stock and Warrant Issuance [Member]	Consideration Shares [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Consideration Shares [Member] Common Stock [Member] Series A Preferred Stock [Member]	Consideration Shares [Member] Common Stock [Member]	Consideration Shares [Member] Additional Paid-in Capital [Member]	Consideration Shares [Member] Retained Earnings [Member]	Consideration Shares [Member] AOCI Attributable to Parent [Member]	Consideration Shares [Member]	Private Placement [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Private Placement [Member] Common Stock [Member] Series A Preferred Stock [Member]	Private Placement [Member] Common Stock [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member] Retained Earnings [Member]	Private Placement [Member] AOCI Attributable to Parent [Member]	Private Placement [Member]	Warrants Issued for Alvogen Agreement Amendment [Member] Common Stock [Member] Series A Preferred Stock [Member]	Warrants Issued for Alvogen Agreement Amendment [Member] Common Stock [Member]	Warrants Issued for Alvogen Agreement Amendment [Member] Additional Paid-in Capital [Member]	Warrants Issued for Alvogen Agreement Amendment [Member] Retained Earnings [Member]	Warrants Issued for Alvogen Agreement Amendment [Member] AOCI Attributable to Parent [Member]	Warrants Issued for Alvogen Agreement Amendment [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2023																																										3,000,000		8,391,940
Balance at Dec. 31, 2023																																											$ 3	$ 8	$ 241,406	$ (253,147)	$ (3)	$ (11,733)
Stock-based compensation																																											0	$ 0	242	0	0	242
Shares issued as repayment of principal and interest for convertible note (in shares)																																										0		143,648
Shares issued as repayment of principal and interest for convertible note																																											0	$ 1	399	0	0	400
Shares issued during period (in shares)	0		34,584												0		575,000												0		270,000
Shares issued during period		$ 0	$ 0	$ 179	$ 0	$ 0	$ 179									$ 0	$ 1	$ 1,343	$ 0	$ 0	$ 1,344									$ 0	$ 0	$ 1,027	$ 0	$ 0	$ 1,027
Fair Value of warrants issued with registered direct offering																																				$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Net loss																																											0	$ 0	0	(6,528)	0	(6,528)
Balance (in shares) at Mar. 31, 2024																																										0		9,772,672
Balance at Mar. 31, 2024																																											0	$ 10	244,599	(259,675)	(3)	(15,069)
Conversion of Series A preferred stock into common stock (in shares)																																										(3,000,000)		300,000
Conversion of Series A preferred stock into common stock																																											(3)	$ 0	3	0	0	0
Vesting of restricted stock awards (in shares)																																										0		57,500
Vesting of restricted stock awards																																											0	$ 0	0	0	0	0
Balance (in shares) at Dec. 31, 2023																																										3,000,000		8,391,940
Balance at Dec. 31, 2023																																											3	$ 8	241,406	(253,147)	(3)	(11,733)
Net loss																																																(16,048)
Balance (in shares) at Sep. 30, 2024																																										0		11,373,246
Balance at Sep. 30, 2024																																											0	$ 11	250,362	(269,195)	0	(18,822)
Balance (in shares) at Mar. 31, 2024																																										0		9,772,672
Balance at Mar. 31, 2024																																											0	$ 10	244,599	(259,675)	(3)	(15,069)
Stock-based compensation																																											0	0	97	0	0	97
Shares issued during period (in shares)	0		247,868												0		698,050
Shares issued during period		0	$ 0	1,228	0	0	1,228									$ 0	$ 1	$ 1,913	$ 0	$ 0	$ 1,914
Net loss																																											0	$ 0	0	(7,897)	0	(7,897)
Balance (in shares) at Jun. 30, 2024																																										0		10,791,630
Balance at Jun. 30, 2024																																											0	$ 11	249,173	(267,572)	(3)	(18,391)
Issuance of shares related to reverse stock split (in shares)																																										0
Contract cost related to Alvogen termination (see Note 9)																																											0	0	1,336	0	0	1,336
Stock-based compensation																																											0	$ 0	104	0	0	104
Shares issued as repayment of principal and interest for convertible note (in shares)																																										0		458,553
Shares issued as repayment of principal and interest for convertible note																																											0	$ 0	829	0	0	829
Shares issued during period (in shares)	0		103,063
Shares issued during period		0	$ 0	219	0	0	$ 219
Net loss																																											0	$ 0	0	(1,623)	0	(1,623)
Common Stock issued in exchange for services (in shares)																																										0		20,000
Common Stock issued in exchange for services																																											0	$ 0	(37)	0	0	(37)
Common Stock issued in exchange for services																																											0	$ 0	37	0	0	37
Balance (in shares) at Sep. 30, 2024																																										0		11,373,246
Balance at Sep. 30, 2024																																											0	$ 11	250,362	(269,195)	0	(18,822)
Reclassification of AOCI upon settlement of Streeterville Note																																											0	$ 0	0	0	3	3
Balance (in shares) at Dec. 31, 2024																																										0		14,591,505
Balance at Dec. 31, 2024																																											0	$ 15	255,035	(278,273)	0	(23,223)
Stock-based compensation																																											0	$ 0	12	0	0	12
Shares issued as repayment of principal and interest for convertible note (in shares)																																										0		1,009,518
Shares issued as repayment of principal and interest for convertible note																																											0	$ 1	2,939	0	0	2,940
Shares issued during period (in shares)								0		1,215,278
Shares issued during period									$ 0	$ 1	$ 3,254	$ 0	$ 0	$ 3,255
Fair Value of warrants issued with registered direct offering																																											0	0	(3,255)	0	0	(3,255)
Amortization of prepaid offering costs																																											0	0	(7)	0	0	(7)
Shares issued as a result of repricing under VWAP (in shares)																						0		303,819
Shares issued as a result of repricing under VWAP																							$ 0	$ 0	$ 629	$ 0	$ 0	$ 629
Net loss																																											0	$ 0	0	(5,512)	0	(5,512)
Balance (in shares) at Mar. 31, 2025																																										0		7,120,120
Balance at Mar. 31, 2025																																											0	$ 17	258,607	(283,785)	0	(25,161)
Balance (in shares) at Dec. 31, 2024																																										0		14,591,505
Balance at Dec. 31, 2024																																											0	$ 15	255,035	(278,273)	0	(23,223)
Shares issued during period (in shares)							1,749,866
Shares issued during period							$ 4,700
Net loss																																																(28,982)
Balance (in shares) at Sep. 30, 2025																																										0		27,682,530
Balance at Sep. 30, 2025																																											0	$ 28	281,473	(307,256)	0	(25,755)
Balance (in shares) at Mar. 31, 2025																																										0		7,120,120
Balance at Mar. 31, 2025																																											0	$ 17	258,607	(283,785)	0	(25,161)
Stock-based compensation																																											0	$ 0	67	0	0	67
Shares issued as repayment of principal and interest for convertible note (in shares)																																										0		1,879,406
Shares issued as repayment of principal and interest for convertible note																																											0	$ 2	5,981	0	0	5,983
Shares issued during period (in shares)	0		399,078
Shares issued during period		0	$ 0	1,012	0	0	$ 1,012
Amortization of prepaid offering costs																																											0	0	(85)	0	0	(85)
Net loss																																											0	$ 0	0	(17,581)	0	(17,581)
Common Stock issued in exchange for services (in shares)																																										0		75,000
Common Stock issued in exchange for services																																											0	$ 0	(150)	0	0	(150)
Common Stock issued in exchange for services																																											0	$ 0	150	0	0	150
Balance (in shares) at Jun. 30, 2025																																										0		19,473,588
Balance at Jun. 30, 2025																																											0	$ 19	265,732	(301,366)	0	(35,615)
Stock-based compensation																																											0	$ 0	68	0	0	68
Shares issued as repayment of principal and interest for convertible note (in shares)																																										0		877,193
Shares issued as repayment of principal and interest for convertible note																																											0	$ 1	2,218	0	0	2,219
Shares issued during period (in shares)	0		1,350,788				1,350,788																																			0		3,959,999
Shares issued during period		$ 0	$ 1	$ 3,739	$ 0	$ 0	$ 3,740																																				0	$ 4	6,209	0	0	6,213
Amortization of prepaid offering costs																																											0	0	(28)	0	0	(28)
Net loss																																											0	$ 0	0	(5,890)	0	(5,890)
Common Stock issued in exchange for services (in shares)																																										0		150,000
Common Stock issued in exchange for services																																											0	$ (1)	(450)	0	0	(451)
Common Stock issued as a result of exercise of warrants (in shares)																																												1,870,962
Common Stock issued as a result of exercise of warrants																																												$ 2	3,085			3,087
Common Stock issued in exchange for services																																											0	$ 1	450	0	0	451
Balance (in shares) at Sep. 30, 2025																																										0		27,682,530
Balance at Sep. 30, 2025																																											$ 0	$ 28	$ 281,473	$ (307,256)	$ 0	$ (25,755)

Note 6 - Furniture and Equipment, Net (Tables)

9 Months Ended

Sep. 30, 2025

Property, Plant and Equipment [Table Text Block]

	September 30,			December 31,
	2025			2024
Medical equipment	$	57		$	-
Computer equipment		32			29
Furniture and fixtures		4			-
Total furniture and equipment		93			29
Less: accumulated depreciation		(24	)		(20	)
Furniture and equipment, net	$	69		$	9

Note 17 - Business Acquisition (Tables)

9 Months Ended

Sep. 30, 2025

Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block]

Preliminary Amount Recognized as of the Acquisition Date (In Thousands)
Assets assumed
Cash and cash equivalents	$	536
Accounts receivable		251
Prepaid expenses		23
Furniture and equipment		64
Right-of-use asset		114
Right-of-use asset - related party		252
Customer relationship		605
Trade name		669
Non-compete agreements		527
Goodwill		610
Total assets acquired	$	3,651
Liabilities assumed
Accounts payable and accrued expenses	$	(26	)
Accrued salaries and benefits		(117	)
Operating lease liability		(109	)
Operating lease liability - related party		(244	)
Total liabilities assumed	$	(496	)
Net assets acquired	$	3,155

Business Combination, Intangible Asset, Acquired, Finite-Lived and Indefinite-Lived [Table Text Block]

				Weighted Average
				Useful Life
	Fair Values			(Years)
Trade name and trademarks	$	669			8.0
Customer relationships		605			3.0
Non-compete agreement		527			5.0
Total intangible assets		1,801
Less accumulated amortization		(24	)
Net carry value	$	1,777

2025	$	98
2026		390
2027		390
2028		329
2029		189
Thereafter		381
Total	$	1,777

Business Combination, Pro Forma Information [Table Text Block]

	For the Three Months Ended September 30,			For the Nine Months Ended September 30,
	2025			2025
Revenue	$	1,128		$	3,147
Net loss		(5,657	)		(28,914	)

	For the Three Months Ended September 30,			For the Nine Months Ended September 30,
	2024			2024
Revenue	$	501		$	2,469
Net loss		(2,026	)		(16,417	)

Note 17 - Business Acquisition - Pro Forma (Details) - Dura Medical [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Revenue	$ 1,128	$ 501	$ 3,147	$ 2,469
Net loss	$ (5,657)	$ (2,026)	$ (28,914)	$ (16,417)

Note 5 - Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Prepaid insurance	$ 658	$ 827
Prepaid clinical development costs	44	824
Other prepaid expense	335	208
Total prepaid expense and other current assets	$ 1,437	$ 1,859

Note 15 - Segment Reporting - Long-lived Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
PPE	$ 93	$ 29
Less: Accumulated Depreciation	(24)	(20)
Net	69	9
Medical Equipment [Member]
PPE	57	0
Computer Equipment [Member]
PPE	32	29
Furniture and Fixtures [Member]
PPE	4	0
Operating Segments [Member]
PPE	93	29
Less: Accumulated Depreciation	(24)	(19)
Net	69	9
Operating Segments [Member] \| Medical Equipment [Member]
PPE	57	0
Operating Segments [Member] \| Computer Equipment [Member]
PPE	33	29
Operating Segments [Member] \| Furniture and Fixtures [Member]
PPE	4	$ 0
Operating Segments [Member] \| NRx Segment [Member]
PPE	29
Less: Accumulated Depreciation	(23)
Net	6
Operating Segments [Member] \| NRx Segment [Member] \| Medical Equipment [Member]
PPE	0
Operating Segments [Member] \| NRx Segment [Member] \| Computer Equipment [Member]
PPE	29
Operating Segments [Member] \| NRx Segment [Member] \| Furniture and Fixtures [Member]
PPE	0
Operating Segments [Member] \| Dura Segment [Member]
PPE	64
Less: Accumulated Depreciation	(1)
Net	63
Operating Segments [Member] \| Dura Segment [Member] \| Medical Equipment [Member]
PPE	57
Operating Segments [Member] \| Dura Segment [Member] \| Computer Equipment [Member]
PPE	4
Operating Segments [Member] \| Dura Segment [Member] \| Furniture and Fixtures [Member]
PPE	$ 4

Note 1 - Organization

9 Months Ended

Sep. 30, 2025

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1. Organization

The Business

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”, the “Company”, “we”, “us” or “our”) is a clinical-stage bio-pharmaceutical company which develops and will distribute, through its wholly-owned operating subsidiary, NeuroRx, Inc., (“NeuroRx”), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, post-traumatic stress disorder (“PTSD”) and schizophrenia. NRx is additionally the founder and majority owner of HOPE Therapeutics, Inc. (“HOPE”), a medical services company that offers interventional psychiatry care to patients with treatment-resistant depression and PTSD with a combination of neuroplastic drugs, transcranial magnetic stimulation (“TMS”), digital therapeutics, and hyperbaric therapy. All of our current drug development activities are focused on drugs that enhance “neuroplasticity” (growth of new brain connections) by modulating the N-methyl-D-aspartate (“NMDA”) receptor in the brain and nervous system, a neurochemical pathway that has been disclosed in detail in our annual filings. The Company has two lead drug candidates – NRX-100, a preservative-free formulation of ketamine for intravenous infusion, and NRX-101, an oral fixed dose combination of D-cycloserine (“DCS”) and lurasidone. NRX-100 and NRX-101 are in the process of submission for Food and Drug Administration (“FDA”) approval as follows:

An Abbreviated New Drug Application (“ANDA”) for NRX-100 was filed, with priority review requested, during the third quarter of 2025. After meeting with the FDA in August 2025, the Company re-filed the ANDA, following FDA notification of approval of a suitability petition for NRx’s proposed strength of preservative-free ketamine, KETAFREE^TM. On November 6, 2025, the Company received a communication from the FDA in which no significant deficiencies were identified in the revised filing. This letter is consistent with the Company’s ambition to launch KETAFREE™ in Q1 2026. The Company has additionally submitted a citizen petition seeking to have benzethonium chloride, a toxic preservative, removed from all current commercial presentations of ketamine.

A New Drug Application (“NDA”) for NRX-100, originally initiated during the fourth quarter of 2024, is expected to be completed in the fourth quarter 2025. This follows award of Fast Track Designation by the FDA for the Company’s expanded indication of “Treatment of Suicidal Ideation in Depression, including Bipolar Depression.” A key element of the Company’s PDUFA strategy has focused on obtaining data to confirm the ketamine efficacy seen in clinical trials conducted under governmental auspices in the US and France. The Company has now arranged to submit Real World Efficacy Data drawn from 65,000 patients treated for depression with intravenous ketamine compared to 6,000 patients treated with intranasal S-ketamine, which will be submitted as part of the NDA. An interim analysis drawn from the first 20,000 such patients suggests that IV ketamine may have a more rapid onset of action and larger magnitude of effect than nasal S-ketamine. The Company has applied to receive a Commissioner’s National Priority Voucher (CNPV), which could significantly reduce review time. The Company has completed all required manufacturing steps and demonstrated room temperature shelf stability to support a three year shelf life.

An NDA filing for NRX-101 has been initiated with the submission of the Module 3 manufacturing file to the FDA. The drug was previously awarded Breakthrough Therapy Designation and accordingly the Company is requesting rolling review from the NDA. Breakthrough Therapy Designation is granted by the FDA to facilitate the development and expedite the review of drugs to treat serious conditions that address an unmet medical need and have demonstrated preliminary evidence of efficacy as determined by the FDA. Based on current data, the Company aims to seek accelerated approval for use of NRX-101 in patients with bipolar depression who exhibit suicidal ideation on currently approved medication.

In the third quarter, the Company was made aware of dramatic findings suggesting that low-dose D-cycloserine (the key ingredient in NRX-101) may increase the antidepressant and antisuicidal effects of TMS by more than 2-fold, as demonstrated in a randomized controlled trial and subsequently confirmed with real world experience and mechanistic studies. Accordingly, the Company has filed a protocol with the FDA to test the use of low-dose NRX-101 in conjunction with the one-day TMS protocol (ONE-D) that has been published in association with the FDA-cleared Ampa Health TMS device. Should this study demonstrate safety and efficacy, it could represent a dramatic expansion of the market for NRX-101 and have the potential to offer patients a rapid remission from severe depression and PTSD with a single day of treatment. Millions of Americans are expected to be treated with TMS in coming years. Success in this planned clinical trial would lead to a 2027 PDUFA date for this previously unanticipated indication.

As previously announced, in February 2024, NRx incorporated HOPE Therapeutics, a medical care delivery organization focused on providing cutting-edge, comprehensive interventional psychiatric treatment with the most effective treatments available, including NMDA-targeted and other neuroplastic drugs, such as ketamine, Spravato and NRX-101, neuromodulatory devices, such as TMS, hyperbaric therapy, digital therapeutics, and medication management.

On December 2, 2024, HOPE formed HTX Management Company, LLC, a wholly owned subsidiary organized as a Delaware limited liability company, for the purpose of supporting future back end operations associated with the growing network of HOPE clinics.

On September 8, 2025, HOPE became a revenue-generating clinical enterprise through its completion of the previously announced acquisition of Dura Medical, LLC (“Dura”), a Florida limited liability company, and a revenue-generating clinical organization with locations in Naples and Ft. Myers, Florida. Founded in 2018, Dura offers precision-based interventional psychiatry services, including ketamine infusion therapy, TMS, Spravato®, stellate ganglion blocks, and psychotherapy (See Note 17).

Subsequent to the third quarter, the Company completed the previously announced addition of Cohen and Associates, based in Sarasota, FL, to the HOPE Network with a strategic minority investment, which expanded HOPE’s footprint on the West Coast of Florida, and related appointment of Dr. Rebecca Cohen as HOPE’s Medical Director. On November 10, 2025, HOPE announced completion of clinical training on the Ampa Health TMS device and initiation of the ONE-D protocol at its Florida locations. The ONE-D protocol has been reported in the peer-reviewed literature to achieve 87% response and 72% remission from severe depression at 6 weeks following a single day of TMS treatment, combined with D-cycloserine. HOPE is the first clinical enterprise to offer this one-day treatment protocol in Florida and one of the first to offer this therapy nationwide.

Through the third quarter of 2025 and in the subsequent period, key achievements by the Company in support of its overall mission to improve and save the lives of patients affected by central nervous system disorders including suicidal depression, chronic pain, post-traumatic stress disorder and schizophrenia include the following:

Drug Development

	●	Grant of fast-track designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medical need. This designation represents an approximately 10-fold expansion of the addressable market to 13 million Americans, compared to the original fast track designation issued in 2017 for bipolar depression alone. The designation letter contains a specific finding that NRX-100 addresses an “unmet medical need.” This is a specific qualifying requirement for the Commissioner’s National Priority Voucher Program.
	●	Re-filing of an ANDA for NRX-100 (preservative-free intravenous ketamine) following an FDA notice of suitability of its suitability petition for NRx’s proposed strength of preservative-free ketamine, KETAFREE^TM. On November 6, 2025, the Company received a communication from the FDA that did not identify any major deficiencies in the revised ANDA submission, consistent with ANDA approval in Q2 2026.
	●	Filing of Commissioner’s National Priority Voucher application for intravenous ketamine (NRX-100). Subsequently, the Company was invited to attend a closed-door listening session with the FDA Commissioner and senior staff.
	●	Submission of stability data for NRX-100 to the manufacturing data on file with the FDA sufficient to support three years of room temperature shelf stability for NRX-100.
	●	Submission of draft labeling for NRX-100 in the treatment of suicidal depression based on the Fast Track Designation received.
	●	Completion of a toxicology assessment of benzethonium chloride, documenting its lack of “Generally Recognized as Safe” (GRAS) status and lack of safety data to support its use in intravenous presentations of ketamine.
	●	Filing of a Citizen Petition with the FDA to seek the removal of benzethonium chloride, a toxic preservative, from all ketamine products for intravenous administration.
	●	Filing of a patent application for NRX-100, the Company’s proprietary preservative-free formulation of intravenous ketamine.
	●	Receipt of filing fee waiver from the FDA for NRX-100.
	●	Filing of module 3 manufacturing data to support an NDA for NRX-101 in the treatment of patients with suicidal bipolar depression and akathisia despite treatment with already-approved medication.

HOPE

	●	Completed the acquisition of Dura and subsequent acquisition of an interest in Cohen.
	●	Appointment of Dr. Rebecca Cohen as HOPE’s Medical Director
	●	Completion of clinical training and First-in-Florida initiation of one-day depression treatment (ONE-D) utilizing D-cycloserine and the Ampa Health FDA-cleared TMS device.

Note 7 - Leases - Schedule of Minimum Lease Payments (Details) $ in Thousands	Sep. 30, 2025 USD ($)
Remainder of 2025	$ 52
2026	202
2027	121
Total	375
Less: imputed interest	(28)
Lease liability	$ 347

Note 11 - Commitments and Contingencies

9 Months Ended

Sep. 30, 2025

Commitments and Contingencies Disclosure [Text Block]

Note 11. Commitments and Contingencies

Sarah Herzog Memorial Hospital License Agreement

The Company is required to make certain payments related to the development of NRX-101 (the “Licensed Product”) in order to maintain the license agreement with the Sarah Herzog Memorial Hospital Ezrat Nashim (“SHMH”) (the “SHMH License Agreement”), including:

Milestone Payments

End of Phase I Clinical Trials of Licensed Product (completed)	$	100,000
End of Phase II Clinical Trials of Licensed Product (completed)	$	250,000
End of Phase III Clinical Trials of Licensed Product	$	250,000
First Commercial Sale of Licensed Product in U.S.	$	500,000
First Commercial Sale of Licensed Product in Europe	$	500,000
Annual Revenues Reach $100,000,000	$	750,000

The milestone payments due above may be reduced by 25% in certain circumstances, and by the application of certain sub-license fees. As of September 30, 2025, the total cumulative payments made under the SHMH License Agreement were $0.5 million, with $0 and $0.2 million in payments made during the three and nine months ended September 30, 2025. There were no payments made during the three and nine months ended September 30, 2024.

Royalties

A royalty in an amount equal to: (a) 1% of revenues from the sale of any product incorporating a Licensed Product when at least one Licensed Patent remains in force, if such product is not covered by a Valid Claim (as defined below) in the country or region in which the sale occurs, or (b) 2.5% of revenues from the sale of any Licensed Product that is covered by at least one Valid Claim in the country or region in which such product is manufactured or sold. A “Valid Claim” means any issued claim in the Licensed Patents that remains in force and that has not been finally invalidated or held to be unenforceable. The royalty rates above may be doubled if we commence a legal challenge to the validity, enforceability, or scope of any of the Licensed Patents during the term of the SHMH License Agreement and do not prevail in such proceeding.

Royalties shall also apply to any revenues generated by sub-licensees from sale of Licensed Products subject to a cap of 8.5% of the payments received by us from sub-licensees in connection with such sales. During the three and nine months ended September 30, 2025 and 2024, no royalty payments were made.

Annual Maintenance Fee

A fixed amount of $100,000 was paid on April 16, 2021 and, thereafter, a fixed amount of $150,000 is due on the anniversary of such date during the term of the SHMH License Agreement. During the nine months ended September 30, 2025 and 2024, the Company recorded $0 in related annual maintenance fee.

Exclusive License Agreement

The Company has entered into a license agreement with Apkarian Technologies LLC to in-license US patent 8,653,120 that claims the use of D-cycloserine for the treatment of chronic pain in exchange for a commitment to pay milestones and royalties as development milestones are reached in the field of chronic pain. The patent is supported by extensive nonclinical data and early clinical data that suggest the potential for NMDA antagonist drugs, such as NRX-101 to decrease both chronic pain and neuropathic pain while potentially decreasing craving for opioids. For the three and nine months ended September 30, 2025 and 2024, the Company has recorded no expenses relating to the licensure of the patent.

Kadima Purchase Agreement

On May 9, 2025, in furtherance of the Company’s previously announced plans for its subsidiary, HOPE, to develop a national network of precision psychiatry clinics. HOPE and its wholly-owned subsidiary, HTX, entered into an Asset Purchase and Contribution Agreement (the “Kadima Purchase Agreement”), with Kadima Medical, Kadima Holdings, Inc. (“Kadima Holdings”), and David Feifel, M.D., PH.D (“Feifel”, and collectively with Kadima Medical and Kadima Holdings, “Kadima”), pursuant to which the Company agreed to purchase and Kadima agreed to sell, certain assets of Kadima, subject to the satisfaction of certain closing conditions (the “Acquisition”).

The Kadima Purchase Agreement contains representations, warranties and covenants of the Company and Kadima that are customary for a transaction of this nature, including among others, covenants by Kadima regarding the validity of certain material contracts entered into between Kadima and third-parties being assigned to the Subsidiaries, title to the assets being sold by Kadima, the condition and sufficiency of the assets being purchased, and Kadima’s rights to its intellectual property, tax liabilities, and the investment representations of Kadima.

The Kadima Purchase Agreement also contains customary indemnification provisions whereby Kadima will indemnify the Company for certain losses arising out of inaccuracies in, or breaches of, the representations, warranties and covenants of Kadima, pre-closing taxes of Kadima, and certain other matters, subject to certain caps and thresholds.

As of the date of this Report, the parties have not closed the Acquisition and the matter has entered arbitration. At this stage of the arbitration, it is too early to determine if the matter would reasonably be expected to have a material adverse effect on our financial condition.

Operating Lease

The Company leases its office space on a month-to-month basis. The rent expense for the three and nine months ended September 30, 2025 was less than $0.1 million and less than $0.1 million, respectively. The rent expense for the three and nine months ended September 30, 2024 was less than $0.1 million and less than $0.1 million, respectively.

The Company also leases two healthcare clinical facilities located in Naples and Fort Myers, Florida under non-cancelable operating lease agreements. Details regarding lease terms, future minimum lease payments, and right-of-use assets and liabilities are disclosed in Note 7.

Legal Proceedings

The Company is, from time to time, involved in various legal proceedings incidental to the conduct of our business. Historically, the outcome of nearly all such legal proceedings has not, in the aggregate, had a material adverse effect on our business, financial condition, results of operations or liquidity. Other than as set forth below, there are no material pending or threatened legal proceedings at this time.

On May 9, 2025, Hope entered into the Kadima Purchase Agreement, pursuant to which the Company agreed to purchase, and Kadima agreed to sell, certain assets of Kadima, subject to the satisfaction of certain closing conditions. As of the date of this Report, the parties have not closed the Acquisition, and the matter has entered arbitration. At this stage of the arbitration, it is too early to determine if the matter would reasonably be expected to have a material adverse effect on our financial condition.

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Net patient service revenue	$ 242	$ 0	$ 242	$ 0
Operating expense:
Cost of patient services	97	0	97	0
Research and development	1,429	611	3,219	5,163
Selling, general and administrative	2,808	2,409	8,492	10,903
Depreciation and amortization expense	26	2	28	4
Settlement (income) expense	(94)	0	6	0
Total operating expenses	4,266	3,022	11,842	16,070
Loss from operations	(4,024)	(3,022)	(11,600)	(16,070)
Other (income) expense:
Interest income	(2)	(6)	(8)	(40)
Interest expense	0	0	0	230
Change in fair value of convertible notes payable	1,502	(1,355)	8,032	(1,014)
Change in fair value of warrant liabilities	4,963	(165)	8,481	(174)
Loss on issuance of Registered Direct Offering	0	0	730	0
Loss on consideration shares and warrants	0	0	1,277	0
Convertible note default penalty	0	0	0	849
Loss on convertible note conversions	772	127	4,239	127
Gain on exercise of warrant liabilities	(5,369)	0	(5,369)	0
Total other expense (income)	1,866	(1,399)	17,382	(22)
Net loss	(5,890)	(1,623)	(28,982)	(16,048)
Comprehensive loss:
Change in fair value of convertible note attributed to credit risk	0	(3)	0	(3)
Other comprehensive loss	0	3	0	3
Comprehensive loss	$ (5,890)	$ (1,626)	$ (28,982)	$ (16,051)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.27)	$ (0.15)	$ (1.54)	$ (1.59)
Weighted average Common Stock outstanding:
Basic and diluted (in shares)	22,231,178	10,973,697	18,881,968	10,108,859

Note 11 - Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2025

Schedule of Milestone Payments [Table Text Block]

End of Phase I Clinical Trials of Licensed Product (completed)	$	100,000
End of Phase II Clinical Trials of Licensed Product (completed)	$	250,000
End of Phase III Clinical Trials of Licensed Product	$	250,000
First Commercial Sale of Licensed Product in U.S.	$	500,000
First Commercial Sale of Licensed Product in Europe	$	500,000
Annual Revenues Reach $100,000,000	$	750,000

Note 7 - Leases

9 Months Ended

Sep. 30, 2025

Lessee, Operating Leases [Text Block]

Note 7. Leases

Accounting for Leases as Lessee

The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use assets (“ROU”), lease liabilities, and lease liabilities – related party. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. None of the leases entered into have an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future payments. Incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in economic environments where the leased asset is located. The ROU assets also include any prepaid lease payments made and initial direct costs incurred and exclude lease incentives. The Company’s lease terms may include options to extend or terminate the lease, which is recognized when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet.

The Company has operating leases for two healthcare clinics in Naples and Fort Myers, Florida:

●

Naples Lease (Related Party): The Company leases its Naples clinic from Dura Properties, LLC, an entity owned and controlled by Dura’s former sole member prior to the acquisition. Following the acquisition on September 8, 2025, the former member became a director and minority shareholder of the Company. Right-of-use (ROU) assets and operating lease liabilities was measured under ASC 805 as if the leases were new at the acquisition date. The amended lease commenced on September 8, 2025 and expires on December 31, 2027. It is non-cancelable and requires monthly base rent of $6,000 (subject to 3% annual escalations), plus $2,000 in common area maintenance charges, and $1,000 in taxes.

●

Fort Myers Lease (Third Party): The Company amended a lease for its Fort Myers clinic on September 8, 2025, with a commencement date of September 8, 2025, and an expiration date of November 30, 2026. Right-of-use (ROU) assets and operating lease liabilities was measured under ASC 805 as if the leases were new at the acquisition date. The amended lease is non-cancellable and requires monthly base rent of $5,000 in the first year, plus $2,000 in common area maintenance charges, subject to 3% annual escalations

The components of lease expense included in the Company’s statement of operations were as follows (in thousands):

		For the three months ended		For the nine months ended
		September 30,		September 30,
	Expense Classification	2025		2025
Operating lease expense:
Amortization of ROU asset	Selling, general and administrative	$	7	$	7
Accretion of operating lease liability	Selling, general and administrative		1		1
Amortization of ROU asset - related party	Selling, general and administrative		8		8
Accretion of operating lease liability - related party	Selling, general and administrative		2		2
Total operating lease expense		$	18	$	18

Other lease expense	Selling, general and administrative		–		–
Total		$	18	$	18

Other information related to leases is as follows:

	As of September 30,
	2025
Weighted-average remaining lease term:
Operating leases (in years)		1.94
Weighted-average discount rate:
Operating leases		6.61	%

Amounts relating to leases were presented on the balance sheet as of September 30, 2025 in the following line items (in thousands):

		As of September 30,
	Balance Sheet Classification	2025
Assets:
Operating lease asset	Right-of-use asset	$	107
Operating lease asset - related party	Right-of-use asset - related party		243
Total non-current lease assets		$	350

Liabilities:
Current
Operating lease liability	Lease liability, short term	$	87
Operating lease liability - related party	Lease liability, short term - related party		102
Non-current
Operating lease liability	Lease liability, non-current		15
Operating lease liability - related party	Lease liability - related party, non-current		143
Total lease liabilities		$	347

The future minimum lease payments required under leases as of September 30, 2025 were as follows (in thousands):

Fiscal Year
Remainder of 2025	$	52
2026		202
2027		121
Total		375
Less: imputed interest		(28	)
Lease liability	$	347

Note 10 - Debt

9 Months Ended

Sep. 30, 2025

Debt Disclosure [Text Block]

Note 10. Debt

Streeterville Convertible Note

On November 4, 2022, the Company issued a convertible note to Streeterville Capital, LLC (“Streeterville”), for an aggregate principal amount of $11.0 million (the “Streeterville Note”). The note was accounted for under the fair value option of ASC 825. All material terms of the Streeterville note have been disclosed in prior filings. As previously disclosed, on April 24, 2024, the Company received written notice from counsel for Streeterville that an alleged event of default occurred with respect to the Note issued by the Company in favor of Streeterville. On August 12, 2024, the Company and Streeterville entered into a Settlement and Release of Claims (the “Settlement Agreement”), whereby the Company and Streeterville agreed to settle all disputes between the parties and release the Company from all obligations to Streeterville under the terms of the Streeterville Note in exchange for a payment of $2.5 million upon the initial closing of the sale of the Anson Notes, and within 60 days thereafter, a second payment of $3.1 million. The Company made the above payments as agreed, thereby consummating the settlement.

The Company evaluated the terms of the Settlement Agreement in accordance with ASC 470-50, Debt Modifications and Extinguishments. Both the Settlement Amendment and the Third Amendment (considered cumulatively with the Settlement Amendment) were deemed to be debt modifications and did not give rise to a debt extinguishment in accordance with ASC Topic 470, Debt, which will be accounted for prospectively. The modifications did not result in recognition of a gain or loss in the condensed consolidated statements of operations as the modifications were not considered debt extinguishments but will impact interest expense and the determination of fair value in future periods.

As of September 30, 2025 and December 31, 2024, the Streeterville Note carried a remaining principal balance of $0. See Note 14 for the reconciliation of the fair values for the periods presented.

Anson Convertible Promissory Notes (the “Anson Notes”)

On August 12, 2024, the Company entered into the Anson Purchase Agreement with the Investors, Anson Investment Master Fund LP and Anson East Master Fund LP (collectively “Anson”). The Company agreed to sell, in three equal tranches, original issue discount Anson Notes in the aggregate principal amount of up to approximately $16.3 million for an aggregate purchase price of up to approximately $15.0 million and warrants to purchase that amount of shares equal to 50% of the principal amount of the Anson Notes divided by the VWAP of the Common Stock, as listed on the Nasdaq Capital Market, on the day prior to the closing of each respective tranche under the Anson Warrants (as defined below).

In connection with the above offering, the Company engaged EF Hutton LLC as placement agent. Pursuant to the terms of the engagement with the placement agent, the Company paid a cash fee of 7% of the gross proceeds the Company receives in the offering at closing. 

On August 14, 2024, the Company entered into the first tranche Senior Secured Convertible Note Agreements (the “First Tranche Notes”) with Anson at various amounts for an aggregate of $5.4 million subject to an original issuance discount of 8% or $435,000, less other cash issuance costs of $521,000, resulting in net cash proceeds of $4.5 million, prior to any allocation to the Anson Warrants. The First Tranche Notes bear interest at a rate of 6% per annum (or 10% during the occurrence of any Event of Default (as defined in the First Tranche Notes)) and have a term of 15 months from the issuance date, maturing on November 14, 2025 (the “First Tranche Maturity Date”) (see Note 12). $2.5 million of the proceeds from the First Tranche Notes were used to make an initial payment to partially satisfy the Streeterville Note in 2024.

On August 14, 2024, in conjunction with the issuance of the First Tranche Notes, the Company issued warrants to purchase up to 1,349,305 shares of Common Stock.

The First Tranche Notes are convertible at the option of the holder at any time after issuance into Common Stock, at a per share conversion price equal to the lower of (a) $2.4168, (the “Fixed Conversion Price”) or (b) a price equal to 92% of the lowest VWAP during the seven trading day period immediately preceding the effective conversion date (the “Alternate Conversion Price”, and together with the Fixed Conversion Price, the “Conversion Price”). If the Conversion Price is less than $0.38 (the “Floor Price”), then in addition to the issuance of Common Stock upon conversion the Company will pay cash as a true-up which is determined by the product of (i) the difference between (y) the Floor Price less (z) the Conversion Price then in effect, multiplied by (ii) the conversion amount that is being paid in Common Stock.

The terms of the First Tranche Notes do not allow any conversion of the First Tranche Notes if it results in Anson owning more than 4.99% of the outstanding shares of Common Stock (the “Beneficial Ownership Limitation”). This limitation can be adjusted up to 9.99% with prior notice, effective 61 days after such notice. Anson must ensure compliance with this limitation when submitting a notice of conversion, and the Company will rely on Anson's representation of compliance.

If the Company issues or grants options for Common Stock at a price lower than the current Conversion Price, the Conversion Price will be adjusted to match this lower price, (the “Base Conversion Price”). The Company must notify Anson of any such issuance, and Anson is entitled to convert shares based on the new Base Conversion Price.

If the Company offers purchase rights to holders of Common Stock, Anson will be entitled to acquire those rights as if they had fully converted the Note, subject to the Beneficial Ownership Limitation. If exercising these rights would exceed the Beneficial Ownership Limitation, the rights will be held in abeyance until they can be exercised without exceeding the limit.

The First Tranche Notes contain mandatory redemption features, whereby if at any time the First Tranche Notes are outstanding, the Company will be required to: (A) use up to 30% of the gross proceeds from any Subsequent Financings (as defined in the Anson Purchase Agreement) in cash, to redeem all or a portion of the Note for an amount equal to the outstanding principal, plus all accrued but unpaid interest, plus all liquidated damages (the “Redemption Obligations”), multiplied by 1.05 (the “Mandatory Redemption Amount”); (B) redeem all of the Redemption Obligations at the Mandatory Redemption Amount in the event of a Change of Control Transaction (as defined in the First Tranche Notes); (C) redeem the Redemption Obligations for the Mandatory Redemption Amount in the event a registration statement is not available for each of the offer and resale of the shares issuable upon conversion of the First Tranche Notes (the “Conversion Shares”); and (D) redeem the Redemption Obligations for the Mandatory Redemption Amount if the stockholder approval is not obtained within 180 days following the date of issuance of the First Tranche Notes.

The First Tranche Notes contain certain covenants, and events of default and triggering events, respectively, which would require repayment of the obligations outstanding pursuant to such instruments. The obligations of the Company pursuant to the First Tranche Notes are (i) secured by all assets of the Company and all subsidiaries of the Company pursuant to the Security Agreement and Patent Security Agreement, dated August 14, 2024, by and among the Company, the subsidiaries of the Company, and the Investors, and (ii) guaranteed jointly and severally by the subsidiaries of the Company pursuant to the Subsidiary Guarantee, dated August 14, 2024, by and among the Company, the subsidiaries of the Company, and the Investors.

Pursuant to the Anson Purchase Agreement, on October 10, 2024 (the “Second Closing Date”), the Company sold a total of $5.4 million in Notes (the “Second Tranche Notes”), subject to an original issue discount of 8% or $435,000 less other cash issuance cost of $375,000, with an aggregate purchase price of approximately $5.0 million, and warrants to purchase up to 1,846,128 shares of Common Stock. The Second Tranche Notes are convertible into Common Stock, at a per share conversion price equal to by the lower of (a) $1.7664 or (b) a price equal to 92% of the lowest VWAP during the seven-trading day period immediately preceding the effective date set forth in a Notice of Conversion delivered by an Investor to the Company. The Conversion Price is subject to, among other customary provisions, downward adjustment in the event of any future issuance by the Company of Common Stock below the then effective Conversion Price. $3.1 million of the proceeds from the Second Tranche Notes were used to satisfy the remaining amount due in connection with the Streeterville Note.

In connection with the above Second Tranche Notes, the Company engaged a placement agent. Pursuant to the terms of the engagement with the Placement Agent, the Company paid a cash fee of 7% of the gross proceeds the Company received in the Third Closing and incurred certain additional other issuance costs and reimbursement for legal counsel disbursements and placement agent, for aggregate issuance costs of approximately $0.4 million.

Pursuant to the Anson Purchase Agreement, on January 28, 2025 (the “Third Closing Date”), the Company sold a total of $5.4 million in Notes subject to an original issue discount of 8% or $0.435 million less other issuance costs of $0.4 million noted below (the “Third Tranche Notes” and collectively with the First Tranche Notes and Second Tranche Notes, the (“Anson Notes”)), with an aggregate purchase price of approximately $5.0 million, and Warrants to purchase up to 862,699 shares of Common Stock. The Third Tranche Notes are convertible into Common Stock, at a per share conversion price equal to by the lower of (a) $3.78 or (b) a price equal to 92% of the lowest VWAP during the seven-trading day period immediately preceding the effective date set forth in a Notice of Conversion delivered by an Investor to the Company. The Conversion Price is subject to, among other customary provisions, downward adjustment in the event of any future issuance by the Company of Common Stock below the then effective Conversion Price.

In connection with the above Third Tranche Notes, the Company paid a cash tail fee to the Placement Agent equal to 7% of the gross proceeds the Company received in the Third Closing and incurred certain additional other issuance costs and reimbursement for legal counsel disbursements, for aggregate issuance costs of approximately $0.4 million.

On or about January 27, 2025, the Company and the Investors entered into a Consent and Waiver Agreement (the “CWA”), relating to certain rights and prohibitions arising under the Anson Purchase Agreement and the Notes. In the CWA, each of the Investors provided its consent under certain restrictive provisions, and waived certain rights, including, among other things, a right to participate in certain Qualified Financings (as defined in the CWA) made by us under the Anson Purchase Agreement and the Notes, the prohibition on issuance of certain equity securities, and waiver of any potential liquidated damages arising under that certain Registration Rights Agreement by and between the Company and the Investors dated August 14, 2024, until March 31, 2025. On March 20, 2025, following the conversion of less than $0.1 million of the Third Tranche Note into 5,463 shares of Common Stock, the Company issued 303,819 shares of Common Stock as Consideration Shares and 303,819 of Consideration Warrants to Anson in accordance with the terms of the CWA (see Note 12).

Due to these embedded features within the Anson Notes, the Company elected to account for the First, Second, and Third Tranche Notes at fair value at inception. Subsequent changes in fair value are recorded as a component of other income (loss) in the condensed consolidated statements of operations. Additionally, the portion of changes in the fair value related to changes in credit risk are recorded to other comprehensive income in the condensed consolidated statements of operations. To determine the initial carrying value of the Notes and the warrants issued to Anson under the First, Second, and Third Tranche Notes (see Note 12), the Company allocated the proceeds using the fair value method. After allocation, the initial carrying value of the First Tranche Notes and the warrants issued to Anson were $2.9 million and $2.1 million, respectively, the initial carrying value of the Second Tranche Notes and the warrants issued to Anson were $3.1 million and $1.9 million, and the initial carrying value of the Third Tranche Notes and the warrants issued to Anson were $2.5 million and $2.5 million, respectively. Refer to Note 14 for the reconciliation of the fair values for the periods presented.

In connection with the Second RD Purchase Agreement, and pursuant to the full ratchet anti-dilution provisions contained in the Anson financing agreements, the Fixed Conversion Price component of the variable conversion formula of the outstanding Anson Notes, and the exercise price of all outstanding Common Stock purchase warrants issued on August 14, 2024, October 10, 2024, January 28, 2025, and January 29, 2025 (collectively, the “Anson Warrants”) were each adjusted to $1.65 per share. In addition, under the full ratchet provision of the warrants’ anti-dilution provision, the number of shares underlying the Anson Warrants was increased by an aggregate of 1,870,960 shares of Company’s Common Stock (see below under “Warrants”). During the quarter ended September 30, 2025, the reduction of the Fixed Conversion Price component of the variable conversion formula of the outstanding Anson Notes pursuant to the anti-dilution provisions is reflected in the change in fair value of convertible notes payable recorded in the consolidated statement of operations for the three and nine months ended September 30, 2025.

The holders of Anson Notes and Anson Warrants, in accordance with an agreement entered into with Anson on September 30, 2025, agreed to, among other things, i) certain trading volume limitations, and ii) a partial exercise on previously issued Anson Warrants for cash. Specifically, if the closing stock price of the Company’s common stock as reported on the Principal Market (as defined in the August 2024 Purchase Agreement) is below $3.25 on any trading day, Anson may not sell, dispose of, or otherwise transfer, in the aggregate, more than 12.5% of the composite daily trading volume of the Company’s common stock on that trading day. In accordance with the agreement, the holders exercised their Anson Warrants for cash, generating net proceeds of $3.09 million and resulting in the issuance of 1,870,960 shares of Company’s Common Stock on September 30, 2025 (see “Warrants” below).

During the three months ended March 31, 2025, Anson converted $1.3 million and less than $0.1 million of principal and interest of the First and Third Tranche Notes, respectively, into Common Stock, resulting in the aggregate issuances of 1,009,518 shares of Common Stock and loss on conversion of $1.6 million. During the three months ended June 30, 2025, Anson converted $4.1 million of principal and interest of the Third Tranche Note into Common Stock, resulting in the issuance of 1,879,406 shares of Common Stock and loss on conversion of $1.9 million. During the three months ended September 30, 2025, Anson converted $1.4 million of principal and interest of the Third Tranche Note into Common Stock, resulting in the issuance of 877,193 shares of Common Stock and loss on conversion of $0.8 million.

During the year ended December 31, 2024, Anson converted $4.2 million of principal and interest of the First Tranche Note into Common Stock, resulting in the issuances of 3,676,796 shares of Common Stock and loss on conversion of $1.3 million. (see Note 11). As of September 30, 2025, the nominal principal and accrued interest balance of the Anson Notes was $5.4 million and $0.3 million, respectively. During the three and nine months ended September 30, 2025, the Company recorded a loss from the change in fair value of the Second and Third Tranche Notes of $0.8 million and $2.7 million, which was recognized in other expense (income) on the condensed consolidated statements of operations as a result of the Company’s election of the fair value option. At September 30, 2025, the effective interest rates of the Second Tranche Note were 172%. See Note 14, “Fair Value Measurements,” for a summary of activity for the Anson Notes.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Note 4 - Revenue (Tables)

9 Months Ended

Sep. 30, 2025

Disaggregation of Revenue [Table Text Block]

	Three Months Ended September 30, 2025		Nine Months Ended September 30, 2025
Procedures income	$	90	$	90
Therapy services		152		152
Total net patient service revenue	$	242	$	242

	Three Months Ended September 30, 2025		Nine Months Ended September 30, 2025
Commercial Insurance	$	156	$	156
Medicare		9		9
Self-Pay		77		77
Total net patient service revenue	$	242	$	242

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

	September 30, 2025
Accounts receivable, gross	$	349
Less: allowance for credit losses		(110	)
Accounts receivable, net	$	239

	September 30, 2025
Commercial insurance	$	198
Medicare		34
Self-pay		117
Accounts receivable, gross	$	349

Accounts Receivable, Allowance for Credit Loss [Table Text Block]

Beginning balance as of December 31, 2024	$	-
Acquisition of Dura (September 8, 2025)		113
Provision (recovery) for expected credit losses		(3	)
Write-offs, net of recoveries		-
Ending Balance as of September 30, 2025	$	110

Note 19 - Subsequent Events (Details Textual) - USD ($) $ in Thousands					1 Months Ended	3 Months Ended	5 Months Ended	9 Months Ended
	Oct. 17, 2025	Oct. 02, 2025	Oct. 01, 2025	Sep. 30, 2025	Nov. 12, 2025	Sep. 30, 2025	Jul. 29, 2024	Sep. 30, 2025	Sep. 30, 2024
Proceeds from Issuance of Common Stock								$ 4,751	$ 0
Anson Warrants [Member]
Proceeds from Warrant Exercises				$ 3,090
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				1,870,960		1,870,960		1,870,960
ATM Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)						1,350,788	385,515	1,749,866
Payments of Stock Issuance Costs						$ 100		$ 100
Subsequent Event [Member] \| Anson Warrants [Member]
Proceeds from Warrant Exercises		$ 3,090	$ 3,090
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,870,960
Subsequent Event [Member] \| ATM Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)					415,097
Proceeds from Issuance of Common Stock					$ 1,400
Payments of Stock Issuance Costs					$ 30
Subsequent Event [Member] \| Cohen LLC [Member]
Payments to Acquire Investments	$ 440

Note 18 - Related Party Transactions

9 Months Ended

Sep. 30, 2025

Note 18. Related Party Transactions

Glytech Agreement

The Company licenses patents that are owned by Glytech, LLC (“Glytech”), pursuant to a license agreement (the “Glytech Agreement”). Glytech is owned by Daniel Javitt, the co-founder and a former director of the Company. The Glytech Agreement requires that the Company pay Glytech for ongoing scientific support and also reimburse Glytech for expenses of obtaining and maintaining patents that are licensed to the Company. During the three months ended September 30, 2025 and 2024, the Company paid Glytech $0 and $0, respectively, for continuing technology support services and reimbursed expenses. During the nine months ended September 30, 2025 and 2024, the Company paid Glytech $0 and $0.3 million, respectively, for continuing technology support services and reimbursed expenses. These support services are ongoing.

The Fourth Amendment to the Glytech Agreement, effective as of December 31, 2020, includes an equity value-triggered transfer of Excluded Technology from Glytech to the Company. The Excluded Technology is defined in the Glytech Agreement as any technology, and any know-how related thereto, covered in the licensed patents that do not recite either D-cycloserine or lurasidone individually or jointly. This definition would cover pharmaceutical formulations, including some that the Company considers “pipeline” or “future product” opportunities, which contain a combination of pharmaceutical components different from those contained in NRX-100 and NRX-101. On November 6, 2022 the Glytech Agreement was amended whereby Glytech agreed to transfer and assign the remainder of the Licensed Technology and the Excluded Technology to the Company for no additional consideration at any time upon receipt of written notice from the Company if, on or prior to June 30, 2024, (i) the value of the Glytech equity holdings in the Company (the “Glytech Equity”) has an aggregate liquidity value of at least $50 million for twenty (20) consecutive trading days immediately preceding any given date and (ii) there are no legal or contractual restrictions on selling all of the securities represented by the Glytech Equity then applicable to Glytech (or reasonably foreseeable to be applicable to Glytech within the following twenty trading days).

Consulting Agreement with Dr. Jonathan Javitt

The Chief Scientist of the Company, Dr. Jonathan Javitt, is a major stockholder of the Company and a member of the Board. Therefore, his services are deemed to be a related party transaction. He served the Company on a full-time basis as chief executive officer under an employment agreement with the Company until March 8, 2022 and currently serves under a consulting agreement with the Company as Chief Scientist thereafter and received compensation of $0.2 million and $0.2 million during the three months ended September 30, 2025 and 2024, respectively, and received compensation of $0.8 million and $0.2 million during the nine months ended September 30, 2025 and 2024, respectively.

On March 29, 2023, the consulting agreement dated March 8, 2022 (the “Javitt Consulting Agreement”) between the Company and Dr. Jonathan Javitt was amended to extend the term of the Javitt Consulting Agreement until March 8, 2024 with automatic annual renewals thereafter unless one party or the other provides notice of non-renewal. The amendment also provided for payment at the rate of $0.6 million per year, payable monthly (i.e., less than $0.1 million per month), and a performance-based annual bonus with a minimum target of $0.3 million, at the discretion of the Board and upon satisfactory performance of the services. The annual discretionary bonus for 2023, if any, may be approved by the Board in 2024 and is payable in March 2024, will be pro-rated from the start of the extension period and is subject to Dr. Javitt’s continued engagement by the Company. The annual discretionary bonus for 2024, if any, may be approved by the board in 2025 and is payable in March 2025, will be pro-rated from the start of the extension period and is subject to Dr. Javitt’s continued engagement by the Company. As of September 30, 2025 and December 31, 2024, the annual discretionary bonus of $0.2 million and $0.2 million is accrued and included within accrued and other current liabilities on the condensed consolidated balance sheets, respectively.

Consulting Agreement with Zachary Javitt

Zachary Javitt is the son of Dr. Jonathan Javitt. Zachary Javitt provides services related to website, IT, and marketing support under the supervision of the Company’s chief executive officer who is responsible for assuring that the services are provided on financial terms that are at market. The Company paid this family member a total of less than $0.1 million and less than $0.2 million during the three months ended September 30, 2025 and 2024, respectively. The Company paid this family member a total of $0.2 million and $0.2 million during the nine months ended September 30, 2025 and 2024, respectively. These services are ongoing.

Included in accounts payable were $0.3 million and less than $0.1 million due to the above related parties as of September 30, 2025 and December 31, 2024, respectively.

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Note 7 - Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2025	Sep. 30, 2024
Amortization of operating right of use assets		$ 15	$ 0
Total operating lease expense	$ 18	18
Other lease expense	0	0
Total	$ 18	$ 18
Operating leases (in years) (Year)	1 year 11 months 8 days	1 year 11 months 8 days
Operating leases	6.61%	6.61%
Nonrelated Party [Member]
Amortization of operating right of use assets	$ 7	$ 7
Accretion of operating lease liability	1	1
Related Party [Member]
Amortization of operating right of use assets	8	8
Accretion of operating lease liability	$ 2	$ 2

Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Antidilutive securities (in shares)	11,695,127	8,729,082
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	119,281	131,833
Restricted Stock [Member]
Antidilutive securities (in shares)	0	33,333
Warrant [Member]
Antidilutive securities (in shares)	9,447,966	5,327,636
Anson Note [Member]
Antidilutive securities (in shares)	2,127,880	3,236,280

Note 13 - Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2025

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

						Weighted
						average
				*Weighted*		*remaining*		*Aggregate*
				*average*		*contractual*		*intrinsic*
	*Number of*			*exercise*		*life (in*		*value (in*
	*shares*			*price*		*years)*		*thousands)*
Outstanding as of December 31, 2023		264,983		$	18.30		7.7	$	75
Options granted		—			—		—		—
Forfeited/Expire		(143,150	)		—		—		—
Outstanding as of December 31, 2024		121,833			22.36		7.0		—
Options granted		547,000			1.84		10.0
Forfeited/Expire		(5,380	)		—		—		—
Outstanding as of September 30, 2025		663,453			5.54		9.0		—
Options vested and exercisable as of September 30, 2025		119,281		$	22.52		6.3	$	—

Nonvested Restricted Stock Shares Activity [Table Text Block]

				Weighted
				Average Grant
				Date Fair
	Awards			Value
Balance as of December 31, 2023 (unvested)		124,166		$	5.20
Granted		—
Vested		(90,833	)	$	4.64
Forfeited		(33,333	)	$	5.20
Balance as of December 31, 2024 (unvested)		—			—
Granted		—		$	—
Vested		—		$	—
Forfeited		—		$	—
Balance as of September 30, 2025 (unvested)		—			—

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three months ended September 30,				Nine months ended September 30,
	2025		2024		2025		2024
	(Unaudited)
Stock-based compensation expense
General and administrative	$	56	$	82	$	123	$	365
Research and development		12		22		24		78
Total stock-based compensation expense	$	68	$	97	$	147	$	339

Note 7 - Leases (Details Textual) $ in Millions	Sep. 30, 2025 USD ($)
Lessee, Number of Operting LEases	2
Naples Lease [Member]
Lessee, Operating Lease, Base Monthly Rent	$ 6
Lessee, Operating Lease, Monthly Base Rent, Annual Escalation	3.00%
Lessee, Operating Lease, Common Area Maintenance Fee	$ 2
Lessee, Operating Lease, Monthly Taxes	1
Fort Myers Lease [Member]
Lessee, Operating Lease, Base Monthly Rent	$ 5
Lessee, Operating Lease, Monthly Base Rent, Annual Escalation	3.00%
Lessee, Operating Lease, Common Area Maintenance Fee	$ 2

Note 19 - Subsequent Events

9 Months Ended

Sep. 30, 2025

Subsequent Events [Text Block]

Note 19. Subsequent Events

On October 17, 2025, the Company, through its subsidiary HOPE completed its acquisition of a strategic and minority interest in Cohen & Associates, LLC, a Florida limited liability company (“Cohen LLC”) for cash consideration of $440 thousand. The acquisition of the interest in Cohen was effectuated pursuant to the terms and conditions of the Membership Interest Purchase Agreement (the “Cohen Purchase Agreement”), dated October 17, 2025, by and among HOPE, Cohen, and Rebecca S. Cohen, MD. The Cohen Purchase Agreement included customary representations and warranties and indemnification provisions and certain post-closing adjustments. The Company is in the process of determining the fair value of the consideration along with the appropriate accounting as it pertains to the acquisition.

In connection with the transaction, Dr. Rebecca Cohen was appointed Medical Director of HOPE, and the terms of employment include certain financial incentives to establish and grow new sites of care owned or operated by HOPE.

From October 6, 2025 through November 12, 2025, the Company sold an aggregate of 415,097 shares of its common stock shares in connection with the at-the-market offering for approximately $1.4 million, net of less than $0.03 million in offering costs.

On October 1, 2025, the Company received $3.09 million in net proceeds related to the September 30, 2025 exercise of 1,870,960 shares underlying Anson Warrants, for which a subscription receivable was recorded on the condensed consolidated balance sheet as of September 30, 2025.

Note 6 - Furniture and Equipment, Net (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Depreciation	$ 2,000	$ 0	$ 4,000	$ 1,000

Note 18 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Jun. 30, 2025	Dec. 31, 2024	Mar. 29, 2023	Nov. 06, 2022
Accounts Payable, Current	$ 4,257		$ 4,257			$ 4,130
Related Party [Member]
Accounts Payable, Current	300		300			100
Glytech License Agreement [Member]
Related Party Transaction, Amounts of Transaction	0	$ 0	0	$ 300
Glytech License Agreement [Member] \| NRX Pharmaceuticals, Inc [Member] \| Minimum [Member]
Investment Owned, Fair Value								$ 50,000
Consultation Agreement with Dr. Jonathan Javitt [Member]
Related Party Transaction, Amounts of Transaction	200	200	800	200
Consultation Agreement with Zachary Javitt [Member]
Related Party Transaction, Amounts of Transaction	$ 100	$ 200	$ 200	$ 200
Consulting Agreement, Annual Payment							$ 600
Consulting Agreement, Monthly Payment							100
Consulting Agreement, Performance Bonus, Target Value							$ 300
Accrued Bonuses, Current					$ 200	$ 200

Note 3 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2025

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	September 30,
	2025		2024
Stock options		119,281		131,833
Restricted stock awards		—		33,333
Common Stock warrants		9,447,966		5,327,636
Common Stock issuable upon conversion of Anson Notes		2,127,880		3,236,280
Totals		11,695,127		8,729,082

Note 13 - Stock-based Compensation - Schedule of Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2025	Dec. 31, 2024	Dec. 31, 2023
Outstanding, balance (in shares)	121,833	264,983
Outstanding, weighted average exercise price (in dollars per share)	$ 22.36	$ 18.3
Outstanding, weighted average remaining contractual term (Year)	9 years	7 years	7 years 8 months 12 days
Outstanding, aggregate intrinsic value	$ 0	$ 0	$ 75
Outstanding, granted (in shares)	547,000	0
Options granted, weighted average exercise price (in dollars per share)	$ 1.84	$ 0
Outstanding, Forfeited/Expire (in shares)	(5,380)	(143,150)
Forfeited/Expire, weighted average exercise price (in dollars per share)	$ 0	$ 0
Options granted, weighted average remaining contractual term (Year)	10 years
Outstanding, balance (in shares)	663,453	121,833	264,983
Outstanding, weighted average exercise price (in dollars per share)	$ 5.54	$ 22.36	$ 18.3
Options vested and exercisable (in shares)	119,281
Options vested and exercisable, weighted average exercise price (in dollars per share)	$ 22.52
Options vested and exercisable, weighted average remaining contractual term (Year)	6 years 3 months 18 days
Options vested and exercisable, aggregate intrinsic value	$ 0

Note 7 - Leases (Tables)

9 Months Ended

Sep. 30, 2025

Lease, Cost [Table Text Block]

		For the three months ended		For the nine months ended
		September 30,		September 30,
	Expense Classification	2025		2025
Operating lease expense:
Amortization of ROU asset	Selling, general and administrative	$	7	$	7
Accretion of operating lease liability	Selling, general and administrative		1		1
Amortization of ROU asset - related party	Selling, general and administrative		8		8
Accretion of operating lease liability - related party	Selling, general and administrative		2		2
Total operating lease expense		$	18	$	18

Other lease expense	Selling, general and administrative		–		–
Total		$	18	$	18

	As of September 30,
	2025
Weighted-average remaining lease term:
Operating leases (in years)		1.94
Weighted-average discount rate:
Operating leases		6.61	%

Leases, Balance Sheet Disclosures [Table Text Block]

		As of September 30,
	Balance Sheet Classification	2025
Assets:
Operating lease asset	Right-of-use asset	$	107
Operating lease asset - related party	Right-of-use asset - related party		243
Total non-current lease assets		$	350

Liabilities:
Current
Operating lease liability	Lease liability, short term	$	87
Operating lease liability - related party	Lease liability, short term - related party		102
Non-current
Operating lease liability	Lease liability, non-current		15
Operating lease liability - related party	Lease liability - related party, non-current		143
Total lease liabilities		$	347

Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]

Fiscal Year
Remainder of 2025	$	52
2026		202
2027		121
Total		375
Less: imputed interest		(28	)
Lease liability	$	347

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2025
Trading Arrangements, by Individual [Table]
Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false

Note 15 - Segment Reporting

9 Months Ended

Sep. 30, 2025

Segment Reporting Disclosure [Text Block]

Note 15. Segment Reporting

The Company operates as two operating and reportable segments, consistent with the manner in which the Chief Executive Officer, designated as the CODM of the Company, evaluates the Company’s performance and allocates resources. The Company’s operations solely consist of the development of novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, and PTSD and now schizophrenia. On September 8, 2025, HOPE completed the previously announced acquisition of Dura, and a revenue-generating clinical organization. Following the acquisition, the Company began generating patient service revenue through Dura’s operations. As a result, the Company now operates in two reportable segments.

The Company generated $242 thousand in revenues during the nine months ended September 30, 2025. The revenue for the three and nine months ended September 30, 2025 represents the revenue generated from Dura. The CODM evaluates performance based on operating expenses and monitors key expense categories related to the Company’s research and development activities, as well as general and administrative functions. As the Company is currently in the pre-revenue phase, the associated expenses above are drivers.

The CODM does not separately evaluate performance by geographic region or product line, as the Company has not yet commenced commercial operations and has limited operations due to the current liquidity and funding of the Company. The Company’s operations are conducted solely within the U.S.

Significant Segment Information

All of the Company’s assets relate to these two operating segments, see the accompanying balance sheets below.

All of the Company’s operating expenses, which consist of research and development and general and administrative expenses, relate to this single operating segment, see the accompanying statements of operations.

The following table reconciles the loss from operations to total loss for the three months ended September 30, 2025 and 2024 (in thousands):

							For the three months
							ended
							September 30,
	NRx			Dura			2025			2024
Expense Category
Income (loss) from operations	$	(4,039	)	$	15		$	(4,024	)	$	(3,022	)
Interest income		(1	)		(1	)		(2	)		(6	)
Interest expense		—			—			—			—
Change in fair value of convertible notes payable		1,502			—			1,502			(1,355	)
Change in fair value of warrant liabilities		4,963			—			4,963			(165	)
Loss on convertible note conversions		772			—			772			127
Gain on exercise of warrants		(5,369	)		—			(5,369	)		—
Net loss	$	(5,906	)	$	16		$	(5,890	)	$	(1,623	)

The following table reconciles the loss from operations to total loss for the nine months ended September 30, 2025 and 2024 (in thousands):

							For the nine months
							ended
							September 30,
	NRx			Dura			2025			2024
Expense Category
(Loss) income from operations	$	(11,616	)	$	15		$	(11,600	)	$	(16,070	)
Interest income		(7	)		(1	)		(8	)		(40	)
Interest expense		—			—			—			230
Change in fair value of convertible notes payable		8,032			—			8,302			(1,014	)
Change in fair value of warrant liabilities		8,481			—			8,481			(174	)
Loss on issuance of Registered Direct Offering		730			—			730			—
Loss on Consideration Shares and Warrants		1,277			—			1,277			—
Convertible note default penalty		—			—			—			849
Loss on convertible note conversions		4,239			—			4,239			127
Gain on exercise of warrants		(5,369	)		—			(5,369	)		—
Net loss	$	(28,999	)	$	16		$	(28,982	)	$	(16,048	)

Long-lived assets consist of furniture and equipment which are included in furniture and equipment, net in the balance sheet. Long-lived assets by year are as follows (in thousands):

	NRx			Dura			September 30, 2025			December 31, 2024
Medical equipment	$	—		$	57		$	57		$	—
Computer equipment		29			4			33			29
Furniture and fixtures		—			4			4			—
Total PPE	$	29		$	64		$	93		$	29
Less: Accumulated Depreciation		(23	)		(1	)		(24	)		(19	)
Net	$	6		$	63		$	69		$	9

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Note 17 - Business Acquisition

9 Months Ended

Sep. 30, 2025

Business Combination [Text Block]

Note 17. Business Acquisitions

Dura Medical, LLC

Transaction Overview

On September 8, 2025, HOPE, a wholly owned subsidiary the Company, completed the acquisition of Dura, a Florida-based behavioral health and interventional psychiatry practice with locations in Naples and Fort Myers, Florida. Dura was founded in 2018 and provides outpatient mental health treatment specializing in evidence-based therapies for treatment-resistant conditions, including depression, anxiety, PTSD, OCD, and chronic pain. Services include ketamine infusion therapy, Spravato® administration, Transcranial Magnetic Stimulation (TMS), Stellate Ganglion Blocks, psychotherapy, and medication management.

The acquisition aligns with the Company’s strategy to expand its clinical care delivery platform through HOPE and establish a multi-site network offering advanced interventional psychiatry services. Management expects the acquisition to accelerate revenue generation and provide a foundation for integrating proprietary therapeutics, including NRX-100 and NRX-101, upon FDA approval.

Consideration Transferred

The preliminary fair value of the consideration transferred was $3.3 million, consisting of cash consideration (subject to customary closing adjustments). The preliminary estimated working capital and other customary closing adjustments resulted in a decrease of approximately $0.1 million to the purchase price, which is included in the total consideration transferred.

The following items were determined to represent post-employment compensation under ASC 805 and ASC 718 and are excluded from the purchase price consideration:

●

Issuance of 6,188 Class A units of HTX as rollover equity subject to conditional vesting; and

●

Contingent consideration of up to $3,000,000 payable over three years based on achievement of specified EBITDA performance targets.

These amounts will be accounted for as compensation expense in future periods as services are rendered.

In connection with the acquisition of Dura, the Company incurred total acquisition-related costs of approximately $0.1 million during the nine months ended September 30, 2025. These costs primarily consist of legal, accounting, consulting fees and a finder fee directly attributable to the transaction. These costs were expensed as incurred and are reflected in general and administrative expenses in the unaudited condensed consolidated statements of operations.

Purchase Price Allocation

The Company has applied the acquisition method of accounting in accordance with ASC 805, Business Combinations (“ASC 805”) and recognized assets acquired, and liabilities assumed at their fair value as of the date of acquisition, with the excess purchase consideration recorded to goodwill. As the Company finalizes the estimation of the fair value of the purchase price and the fair value of the assets acquired and liabilities assumed, additional adjustments may be recorded during the measurement period (a period not to exceed 12 months from the acquisition date).

The Company recorded all tangible and identifiable intangible assets acquired and liabilities assumed at their preliminary estimated fair values as of the acquisition date. The preliminary allocation is as follows:

Preliminary Amount Recognized as of the Acquisition Date (In Thousands)
Assets assumed
Cash and cash equivalents	$	536
Accounts receivable		251
Prepaid expenses		23
Furniture and equipment		64
Right-of-use asset		114
Right-of-use asset - related party		252
Customer relationship		605
Trade name		669
Non-compete agreements		527
Goodwill		610
Total assets acquired	$	3,651
Liabilities assumed
Accounts payable and accrued expenses	$	(26	)
Accrued salaries and benefits		(117	)
Operating lease liability		(109	)
Operating lease liability - related party		(244	)
Total liabilities assumed	$	(496	)
Net assets acquired	$	3,155

Certain adjustments of approximately $0.1 million to the purchase price were recorded, decreasing the purchase price during the measurement period ended September 30, 2025. Changes to the provisional amounts recognized at the acquisition date—if based on new information about facts and circumstances that existed as of the acquisition—must be accounted for retrospectively during the measurement period.

Intangible Assets

The Company identified the following finite-lived intangible assets, which will be amortized on a straight-line basis over their estimated useful lives once finalized:

●

Trade Name – includes the “Dura Medical” name and associated trademarks.

●

Customer relationship – representing the value of established patient relationships and referral sources.

●

Non-Compete Agreements – arising from restrictive covenants in the purchase agreement.

The acquired intangible assets are being amortized over their estimated useful lives as follows (in thousands):

				Weighted Average
				Useful Life
	Fair Values			(Years)
Trade name and trademarks	$	669			8.0
Customer relationships		605			3.0
Non-compete agreement		527			5.0
Total intangible assets		1,801
Less accumulated amortization		(24	)
Net carry value	$	1,777

The Company incurred amortization expense of $24 thousand during the three and nine months ended September 30, 2025.

As of September 30, 2025, the maturities of the Company’s intangible assets were as follows (in thousands):

2025	$	98
2026		390
2027		390
2028		329
2029		189
Thereafter		381
Total	$	1,777

Goodwill

Goodwill of approximately $0.6 million represents the excess of the purchase consideration over the fair value of net assets acquired and was recognized in connection with the acquisition. None of the goodwill is expected to be deductible for tax purposes. The goodwill is assigned to the Dura subsidiary. The goodwill primarily represents expected synergies, assembled workforce, and future growth potential. No goodwill arose from step acquisitions or non-controlling interests.

Measurement Period

The Acquisition was recorded as a business combination on a preliminary valuation of assets acquired and liabilities assumed at their acquisition date fair values using unobservable inputs that are supported by little or no market activity and are significant to their fair value of the assets and liabilities (“Level 3” inputs). We expect to complete our purchase price allocation, as well as our fair value estimate of the purchase price consideration as soon as reasonably possible, not to exceed one year from the acquisition date. Adjustments to the preliminary purchase price and allocation could be material. Goodwill and intangible assets represent the excess of the purchase price consideration over the preliminary valuation of the other net assets acquired.

As of September 30, 2025, the purchase price allocation remains preliminary, and the purchase price may be subject to final adjustments. The Company is continuing to assess the fair values of certain identifiable intangible assets and contingent liabilities, including the potential adjustment to exchangeable shares.

Pro-Forma Financial Information (Unaudited)

The following unaudited pro forma information presents the consolidated results of Dura included in the Company’s unaudited condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2025, as if the acquisition was made on January 1, 2025, and operations for the three and nine months ended September 30, 2024, as if the Acquisition had occurred on January 1, 2024. The unaudited pro forma information is presented for illustrative purposes only. It is not necessarily indicative of the results of operations of future periods, or the results of operations that actually would have been realized had the entities been a single company during the periods presented or the results that the combined company will experience after the acquisition. The unaudited pro forma information does not give effect to the potential impact of current financial conditions, regulatory matters or any anticipated synergies, operating efficiencies or cost savings that may be associated with the acquisition. The unaudited pro forma information also does not include any integration costs or remaining future transaction costs that the companies may incur related to the acquisition as part of combining the operations of the companies.

The unaudited pro forma consolidated results of revenue and net loss, assuming the acquisition had occurred on January 1, 2025, is as follows (in thousands):

	For the Three Months Ended September 30,			For the Nine Months Ended September 30,
	2025			2025
Revenue	$	1,128		$	3,147
Net loss		(5,657	)		(28,914	)

The unaudited pro forma consolidated results of revenue and net loss, assuming the acquisitions had occurred on January 1, 2024, is as follows (in thousands):

	For the Three Months Ended September 30,			For the Nine Months Ended September 30,
	2024			2024
Revenue	$	501		$	2,469
Net loss		(2,026	)		(16,417	)

The unaudited pro forma results for the three and nine months ended September 30, 2025, include material nonrecurring adjustments of $0.1 million and $0.5 million, respectively, related to the amortization of intangible assets acquired in connection with the Dura acquisition.

The unaudited pro forma results for the three and nine months ended September 30, 2024, include material nonrecurring adjustments of $0.3 million and $0.9 million, respectively, related to the amortization of intangible assets acquired in connection with the Dura acquisition and approximately $0.1 million related to the finders’ fees incurred and earned upon closing of the transaction.

For the three and nine months ended September 30, 2025, the operating expenses of Dura included in the Company’s consolidated statement of operations and comprehensive loss were insignificant to the Company’s financial results. Net patient service revenue and net income attributable to Dura for the nine months ended September 30, 2025, and included in the Company’s consolidated statement of operations, were $242 thousand and $16 thousand, respectively.

The entire disclosure for business combination.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-38

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 46
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-46

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 43
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-43

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 45
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-45

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-29

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-29

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-4

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 40
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479326/805-40-45-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-30/tableOfContent

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-20/tableOfContent

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-5

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-10/tableOfContent

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2025	Jun. 30, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024
ATM Offering [Member]
Shares issued during period, offering costs	$ 110	$ 26	$ 31	$ 118	$ 48
Common Stock and Warrant Issuance [Member]
Shares issued during period, offering costs				$ 494	$ 481
Shares issued during period, offering costs	$ 321

Note 14 - Fair Value Measurements - Schedule of Recurring Level 3 Fair Value Changes (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024
Change in fair value of warrant liabilities	$ 4,963	$ 8,500		$ (165)			$ 8,481	$ (174)
Anson Convertible Notes [Member]
Convertible note payable - current portion as of September 30, 2025	9,909						9,909
Convertible note payable, net of current portion as of September 30, 2025	0						0
Anson Convertible Notes [Member]
Balance	9,854	8,397	$ 6,257				6,257
Fair value of Anson III Note at issuance			2,522
Conversion and repayments of principal and interest (shares)	(1,447)	(4,108)	(1,347)
Fair value adjustment through earnings	1,502	5,565	965
Fair value of Anson Notes as of March 31, 2025	9,909	9,854	8,397				9,909
Loss (gain) upon re-measurement	1,502	5,565	965
Warrants [Member]
Balance	16,266	9,852	5,639	8	$ 26	$ 17	5,639	17
Fair value adjustment through earnings				(165)	(18)	9
Fair value of Anson Notes as of March 31, 2025	15,860	16,266	9,852	1,902	8	26	$ 15,860	$ 1,902
Loss (gain) upon re-measurement				(165)	$ (18)	$ 9
Initial recognition of issuance of warrants			7,109	$ 2,059
Change in fair value of warrant liabilities	4,963	$ 6,414	$ (2,896)
Fair Value of Anson warrants exercised	$ (5,369)

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2025	Dec. 31, 2024
Preferred stock, par value (in dollars per share)	$ 0.001
Preferred stock, authorized (in shares)	50,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	500,000,000	500,000,000
Common stock, issued (in shares)	27,682,530	14,591,505
Common stock, outstanding (in shares)	27,682,530	14,591,505
Nondesignated Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	50,000,000	50,000,000
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	12,000,000	12,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

Note 12 - Equity

9 Months Ended

Sep. 30, 2025

Equity [Text Block]

Note 12. Equity

Preferred Stock

Pursuant to the terms of the Company’s Second Amended and Restated Certificate of Incorporation, the Company has 50,000,000 shares of preferred stock authorized with a par value of $0.001, of which 12,000,000 were designated Series A Convertible Preferred Stock (“Series A Preferred Stock”). In August 2023, the Company sold and issued 3.0 million shares of Series A Preferred Stock for an aggregate cash purchase price of $1.2 million. During March 2024, holders of the Company’s Series A Preferred Stock elected to convert 3.0 million shares of Series A Preferred into 300,000 shares of Common Stock. As of September 30, 2025, no shares of Series A Preferred Stock remained issued or outstanding.

Common Stock

Pursuant to the terms of the Company’s Second Amended and Restated Certificate of Incorporation, the Company has authorized 500,000,000 shares of Common Stock.

On January 2, 2024, the Company issued 143,648 shares of Common Stock as payment for the $0.4 million minimum payment to Streeterville related to principal and interest payments on the Streeterville Note.

From February 20, 2024 to July 29, 2024, the Company announced that it entered into multiple at-the-market purchase agreements (the “ATM Purchase Agreements”) subject to standard closing conditions where accredited investors purchased 385,515 shares of unregistered Common Stock at a range of $2.42 – $7.10 per share. On April 15, 2024, the Company increased the maximum aggregate offering amount of the shares of Common Stock issuable under that certain at-the-market offering agreement, dated August 14, 2023 (the “Offering Agreement”), with H.C. Wainwright & Co., and filed a prospectus supplement (the “Current Prospectus Supplement”) under the Offering Agreement for an aggregate of $4.9 million. The Company suspended the at-the-market offering from August 14, 2024 through April 17, 2025. On April 17, 2025, the Company reinstated the at-the-market offering and increased the maximum aggregate offering amount and filed a prospectus supplement under the Offering Agreement for an aggregate of $20,000,000. During the three months ended September 30, 2025, the Company sold an aggregate of 1,350,788 shares of its Common Stock shares for approximately $3.7 million, net of less than $0.1 million in transaction costs. During the nine months ended September 30, 2025, the Company sold an aggregate of 1,749,866 shares of its Common Stock shares for approximately $4.7 million, net of $0.1 million in transaction costs.

On February 27, 2024, the Company entered into an underwriting agreement (the “February Underwriting Agreement”) with EF Hutton LLC (the “Representative”), as the representative of the several underwriters named therein (the “February Underwriters”), relating to an underwritten public offering (the “February 2024 Public Offering”) of 500,000 shares (the “February Shares”) of the Company’s Common Stock (the “February Shares”). The public offering price for each share of Common Stock was $3.00, and the February Underwriters purchased the shares of Common Stock pursuant to the February Underwriting Agreement at a price for each share of Common Stock of $2.76. Pursuant to the February Underwriting Agreement, the Company also granted the Representative a 45-day option to purchase up to an additional 75,000 shares (the “February Option Shares”) of the Common Stock on the same terms as the February Shares sold in the February 2024 Public Offering (the “February Over-Allotment Option”). On February 28, 2024, the February 2024 Public Offering closed (the “February Closing Date”). The aggregate net cash proceeds to the Company from the February 2024 Offering proceeds were approximately $1.3 million after offering costs of approximately $0.4 million. On March 5, 2024, the February Underwriters of the previously announced underwritten public offering of the Company exercised their option in accordance with the February Underwriting Agreement, dated February 27, 2024, by and between the Company and the Representative, as representative of the several underwriters named therein, to purchase up to an additional 75,000 shares of the Common Stock, at a public offering price of $3.00 per share (the “February Overallotment Exercise”). The February Overallotment Exercise closed on March 6, 2024. The aggregate net cash proceeds to the Company from the February Overallotment Exercise were approximately $0.2 million. The Company accrued additional offering costs of approximately $0.2 million.

On February 29, 2024, the Company entered into a securities purchase agreement with an investor providing for the issuance and sale of 270,000 shares of Common Stock and warrants to purchase up to 270,000 shares of Common Stock (the “February Warrants”) at a price of $3.80 per share of Common Stock and accompanying warrant, which represents a 26.7% premium to the offering price in February 2024 Public Offering. The Common Stock and the February Warrants were offered pursuant to a private placement (the “February 2024 Private Placement”) under Section 4(a)(2) of the Securities Act of 1933, as amended. The aggregate net cash proceeds to the Company from the February 2024 Private Placement were approximately $1.0 million.

On April 18, 2024, the Company entered into an underwriting agreement (the “April Underwriting Agreement”) with the Representative, as the representative of the several underwriters named therein (the “April Underwriters”), relating to an underwritten public offering (the “April 2024 Public Offering”) of 607,000 shares (the “April Shares”) of Common Stock. The public offering price for each share of Common Stock was $3.30. Pursuant to the April Underwriting Agreement, the Company also granted the Representative a 45-day option to purchase up to an additional 91,050 shares (the “April Option Shares”) of the Common Stock on the same terms as the April Shares sold in the April 2024 Public Offering (the “April Over-Allotment Option”). On April 19, 2024, the Offering closed (the “April Closing Date”). Net proceeds from the April 2024 Public Offering were approximately $1.6 million after offering costs of approximately $0.4 million. On May 23, 2024, the April Underwriters of the previously announced underwritten public offering of the Company exercised their option in accordance with the April Underwriting Agreement, dated April 18, 2024, by and between the Company and the Representative, as representative of the several underwriters named therein, to purchase up to an additional 91,050 shares of the Company’s Common Stock, at the public offering price of $3.30 per share (the “April Overallotment Exercise”). The April Over-Allotment Exercise was exercised in full and closed on May 23, 2024. The net cash proceeds to the Company from the April Overallotment Exercise were approximately $0.2 million which include offering costs of less than $0.1 million.

On August 28, 2024, the Company issued 20,000 shares of Common Stock in relation to consulting services performed by a third party. The fair value of the Common Stock on the date of issuance was less than $0.1 million.

During the year ended December 31, 2024, Anson converted $4.2 million of principal and interest of the First Tranche Note into Common Stock, resulting in the issuances of 3,676,796 shares of Common Stock valued at $5.5 million based on the market price of the Common Stock at the date of Common Stock issuance resulting in a loss on conversion of $1.3 million (see Note 10).

On January 27, 2025, the Company entered into a securities purchase agreement (the “First RD Purchase Agreement”) with Anson for the sale by the Company of 1,215,278 shares (the “First RD Shares”) of Common Stock to the Investors, at a purchase price of $2.88 per share, in a registered direct offering (the “First Registered Direct Offering”). Concurrently with the sale of the First RD Shares, pursuant to the First RD Purchase Agreement the Company also sold to the investors unregistered Common Stock purchase warrants (the “First RD Warrants”) to purchase up to an aggregate of 1,215,278 shares of Common Stock (the “First RD Warrant Shares”), in a private placement. Subject to certain beneficial ownership limitations, the First RD Warrants are immediately exercisable upon issuance at an exercise price equal to $2.88 per share of Common Stock, subject to adjustments as provided under the terms of the First RD Warrants. The closing of the sales of these securities under the First RD Purchase Agreement occurred on or about January 29, 2025 (the “First RD Closing Date”), resulting in net proceeds to the Company of approximately $3.255 million after transaction costs. The First RD Warrants are exercisable for five years from the First RD Closing Date. The Company intends to use the net proceeds from the transactions for general corporate purposes, including the funding of certain capital expenditures.

On or around January 27, 2025, the Company and Anson entered into a consent and waiver agreement related to the First RD Purchase Agreement and the Notes. Under this agreement, the investors agreed to waive certain rights and restrictions, including their right to participate in certain future financings, restrictions on the Company issuing specific equity securities, and any potential liquidated damages under the Registration Rights Agreement dated August 14, 2024. These waivers are effective through and expired as of March 31, 2025.

As consideration for these waivers, the Company agreed to issue additional compensation to the investors if the volume-weighted average price (VWAP) of the Company’s Common Stock is lower than the original purchase price at the time investors submit their first conversion notice for Anson Notes issued in the Second or Third Closing. This compensation includes additional shares of Common Stock (the “Consideration Shares”) and warrants to purchase an equal number of shares (the “Consideration Warrants”). The exercise price of the warrants is based on a VWAP-Based Adjustment, calculated as the greater of (a) the VWAP on the trading day before the conversion notice, or (b) 80% of the closing price on the day before the Registered Direct Offering. As of September 30, 2025, the obligation under this provision has been fully satisfied. On March 20, 2025, following the conversion of less than $0.1 million of the Third Tranche Note into 5,463 shares of Common Stock, the Company issued 303,819 shares of Common Stock Consideration Shares and 303,819 of Consideration Warrants to Anson in accordance with the terms of the CWA.

The gross proceeds to the Company from the offerings were approximately $3.5 million, before deducting offering expenses of $0.2 million and excluding the proceeds, if any, from the exercise of the First RD Warrants. As discussed above, on January 29, 2025, in conjunction with the issuance of the First RD Shares, the Company issued First RD Warrants to purchase up to 1,215,278 shares of the Company’s Common Stock which were classified as a liability. The First RD Warrants have an exercise price of $2.88 per share and have a contractual term of five years expiring on January 29, 2030. The measurement of fair value of the First RD Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $2.07, exercise price of $2.88, term of five years, volatility of 115.8%, and risk-free rate of 4.00%). The grant date fair value of these First RD Warrants was estimated to be $3.983 million on January 29, 2025. As the fair value of the liabilities exceeded the net proceeds received of $3.255 million, the Company recognized the excess of the fair value over the net proceeds received of $3.255 million as a loss upon issuance of First RD Shares of $0.7 million which is included in other expense (income) in the condensed consolidated statement of operations for the nine months ended September 30, 2025.

During the first quarter of fiscal 2025, Anson converted $1.3 million of principal and interest of the First Tranche Note into Common Stock, resulting in the issuance of 1,004,055 shares of Common Stock valued at $2.9 million based on the market price of the Common Stock at the date of the Common Stock issuance resulting in a loss on conversion of $1.6 million (See Note 10).

During the first quarter of fiscal 2025, Anson converted less than $0.1 million of principal and interest of the Third Tranche Note into Common Stock, resulting in the issuance of 5,463 shares of Common Stock valued at less than $0.1 million based on the market price of the Common Stock at the date of the Common Stock issuance resulting in a loss on conversion of less than $0.1 million (See Note 10).

During the second quarter of fiscal 2025, Anson converted $4.1 million of principal and interest of the Third Tranche Note into Common Stock, resulting in the issuance of 1,879,406 shares of Common Stock valued at $6.0 million based on the market price of the Common Stock at the date of the Common Stock issuance resulting in a loss on conversion of $1.9 million (See Note 10).

During the third quarter of fiscal 2025, Anson converted $1.4 million of principal and interest of the Third Tranche Note into Common Stock, resulting in the issuance of 877,193 shares of Common Stock valued at $2.2 million based on the market price of the Common Stock at the date of the Common Stock issuance resulting in a loss on conversion of $0.8 million (See Note 10).

On March 20, 2025, following the conversion of less than $0.1 million of the Third Tranche Note into 5,463 shares of Common Stock, the Company issued 303,819 shares of Common Stock Consideration Shares and 303,819 of Consideration Warrants to Anson in accordance with the terms of the CWA. As a result of this adjustment, the exercise price of the RD Warrants was updated to $2.30 as of March 20, 2025. Upon conversion or extinguishment, ASC 470-50-40-2 requires that any difference between the carrying amount of the debt and the fair value of consideration transferred be recognized as a gain or loss in the statement of operations. The Consideration Shares, being equity-classified, are recognized at fair value with credit to Common Stock and additional paid in capital. The Consideration Warrants, liability-classified under ASC 815-40, were initially recognized at fair value, with changes in fair value subsequently recognized through earnings. In accordance with the CWA, the Company recorded loss on issuance of the Consideration shares and the Consideration Warrants in total of $1.28 million recognized within other expense (income) during the nine months ended September 30, 2025, within accompanying condensed consolidated statements of operations and comprehensive loss.

On May 15, 2025, the Company granted 75,000 shares of fully vested Common Stock to a vendor in accordance with the vendor agreement. The value of the fully vested shares granted was determined by the value of the stock on the quoted trading price of $2.08 and an aggregate of approximately $0.2 million was recorded as expense within the accompanying condensed consolidated statement of operations for the three and nine months ended September 30, 2025.

On August 18, 2025, the Company entered into a securities purchase agreement (the “Second RD Purchase Agreement”) with certain accredited investors for the sale of an aggregate of 3,959,999 shares of the Company’s Common Stock, at a purchase price of $1.65 per share (the “Second Registered Direct Offering”). The Second Registered Direct Offering closed on August 18, 2025, and resulted in net proceeds of approximately $6.2 million, after deducting placement agent fees and other offering-related expenses of approximately $0.3 million. Concurrently with the execution of the Second RD Purchase Agreement, the purchasers of the Second Registered Direct Offering entered into Lock-Up Agreements with the Company, pursuant to which they agreed not to sell, transfer, or otherwise dispose of the shares of Common Stock, subject to certain exceptions, without the prior written consent of the Company until August 19, 2026.

On July 17, 2025, the Company granted 150,000 shares of fully vested Common Stock to a vendor in accordance with the vendor agreement. The value of the fully vested shares granted was determined by the value of the stock on the quoted trading price of $3.00 and an aggregate of approximately $0.45 million was recorded as expense within the accompanying condensed consolidated statement of operations for the three and nine months ended September 30, 2025.

On September 30, 2025, the 1,870,960 shares underlying the Anson Warrants, that were issued with the original convertible notes, were exercised for cash proceeds of $3.09 million. The fair value of the exercised warrants, which were initially recorded as warrant liability, was determined to be $5.37 million as of the exercise date, resulting in a gain of $5.37 million upon settlement of these warrant liabilities exercises, representing the difference between the fair value of the exercised Anson warrants and the cash proceeds received. Because the exercise proceeds were received subsequent to September 30, 2025, the Company recorded a subscription receivable asset of $3.09 million as of September 30, 2025. The gain on Anson warrants exercised was recognized within other expense (income) for the three and nine months ended September 30, 2025.

Warrants

Substitute Warrants – Liability

On May 24, 2021, the Company completed the merger (“Merger”) under the Agreement and Plan of Merger dated December 13, 2020, as amended, among the Company (formerly Big Rock Partners Acquisition Corp.), NeuroRx, Inc., and Big Rock Merger Corp., a wholly owned subsidiary of our company. In the transaction, Big Rock Merger Corp. merged with and into NeuroRx, with NeuroRx continuing as the surviving entity. In connection with the Merger in 2021, each warrant to purchase shares of Common Stock of NRx that was outstanding and unexercised immediately prior to the effective time (whether vested or unvested) was assumed by Big Rock Partners Acquisition Corp. (“BRPA”) and converted into a warrant, based on the exchange ratio (of 0.316), that will continue to be governed by substantially the same terms and conditions, including vesting, as were applicable to the former warrant (the “Substitute Warrants”). There were 3,792,970 warrants outstanding and unexercised at the effective time. As these Substitute Warrants meet the definition of a derivative as contemplated in FASB ASC Topic 815, based on provisions in the warrant agreement related to the Earnout Shares Milestone and the Earnout Cash Milestone and the contingent right to receive additional shares for these provisions, the Substitute Warrants were recorded as derivative liabilities on the condensed consolidated balance sheet and measured at fair value at inception (on the date of the Merger) and at each reporting date in accordance with FASB ASC Topic 820, with changes in fair value recognized in the statements of operations in the period of change. Refer to Note 14 for further discussion of fair value measurement of the warrant liabilities.

Assumed Public Warrants – Equity

Prior to the Merger, the Company had 3,450,000 warrants outstanding (the “Public Warrants”) to purchase up to 345,000 shares of Common Stock. Each Public Warrant entitles the holder to purchase one-tenth share of Common Stock at an exercise price of $115 per share. The Public Warrants became exercisable at the effective time of the Merger and expire five years after the effective time on or earlier upon their redemption or liquidation of the Company.

During the three and nine months ended September 30, 2025 and 2024 no Public Warrants were exercised. The outstanding balance of these public warrants remains in equity. At September 30, 2025 and December 31, 2024, there were 3,448,856 Public Warrants outstanding to purchase up to 344,886 shares of Common Stock.

Assumed Private Placement Warrants – Liabilities

Prior to the Merger, the Company had outstanding 136,250 Private Placement Warrants (the “Private Placement Warrants”) to purchase up to 13,625 shares of Common Stock. The Private Placement Warrants are not indexed to the Company’s common shares in the manner contemplated by FASB ASC Topic 815-40-15 because the holder of the instrument is not an input into the pricing of a fixed-for-fixed option on equity shares. The Company classifies the Private Placement Warrants as derivative liabilities in its condensed consolidated balance sheets as of September 30, 2025 and December 31, 2024. The Company measures the fair value of the Private Placement Warrants at the end of each reporting period and recognizes changes in the fair value from the prior period in the Company’s statements of operations for the current period.

The Company recognized a change in fair value of the Private Placement Warrants for the three and nine months ended September 30, 2025 and 2024 in the accompanying statement of operations. See Note 14 for discussion of the fair value measurement of the Company’s warrant liabilities.

Investor Warrants – Equity

As discussed above, on February 28, 2024, in conjunction with the sale of 270,000 shares of the Common Stock, the Company issued February 2024 Warrants to purchase up to 270,000 shares of Common Stock which were classified in stockholder’s equity. The February 2024 Warrants have an exercise price of $3.80 per share, are initially exercisable beginning six months following the date of issuance and will expire five years from the date of issuance. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.59, exercise price of $3.80, term of 5 years, volatility of 178.10%, risk-free rate of 4.26%, and expected dividend rate of 0%). The allocated fair value of the February 2024 Warrants on the grant date was $0.5 million and is recorded within additional paid-in capital.

On February 28, 2024, the Company issued to the Representative the Underwriter’s Warrant to purchase up to 25,000 shares of Common Stock. The Underwriter’s Warrant is exercisable six months following the date of the Underwriting Agreement and terminates on the five-year anniversary of the date of the Underwriting Agreement. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.05, exercise price of $3.30, term of 5 years, volatility of 178.10%, risk-free rate of 4.26%, and expected dividend rate of 0%). The allocated fair value of the Underwriter's Warrants on the grant date was $0.1 million and is recorded as a charge to additional paid-in capital.

On March 5, 2024, the Company issued Underwriter’s Warrant to purchase up to 3,750 shares of Common Stock in relation to the exercise of the February Over-Allotment Option. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.05, exercise price of $3.30, term of 5 years, volatility of 178.10%, risk-free rate of 4.12%, and expected dividend rate of 0%). The allocated fair value of the Underwriter's Warrants on the grant date was less than $0.1 million and is recorded as a charge to additional paid-in capital.

On April 19, 2024, the Company issued to the Representative the April Underwriter Warrant to purchase up to 30,350 shares of Common Stock (the “April Underwriter Warrant”). The April Underwriter Warrant is exercisable for six months following the date of the Underwriting Agreement and terminates on the five-year anniversary of the date of the Underwriting Agreement. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.04, exercise price of $3.63, term of 5 years, volatility of 178.10%, risk-free rate of 4.66%, and expected dividend rate of 0%). The allocated fair value of the April Underwriter Warrant on the grant date was less than $0.1 million and is recorded as a charge to additional paid-in capital.

On May 23, 2024, the Company issued Underwriter’s Warrant to purchase up to 4,553 shares of Common Stock in relation to the exercise of the April Over-Allotment Option. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.62, exercise price of $3.63, term of 5 years, volatility of 178.10%, risk-free rate of 4.52%, and expected dividend rate of 0%). The allocated fair value of the Underwriter's Warrants on the grant date was less than $0.1 million and is recorded as a charge to additional paid-in capital.

Alvogen Warrants – Equity

In conjunction with the amended Licensing Agreement with Alvogen discussed in Note 9, on February 7, 2024 the Company issued warrants to purchase up to 419,598 shares of Common Stock. The warrants have an exercise price of $4.00 per share, are exercisable immediately following the date of issuance, will expire three years from the date of issuance, and may also be exercised on a cashless basis if there is no effective registration statement available for the resale of the shares of Common Stock underlying the warrants. The warrants are subject to a beneficial ownership limitation of 4.99% post-exercise, with the exception that the beneficial ownership limitation may be waived up to a maximum of 9.99% at the election of the holder, with not less than 61 days prior notice. The measurement of fair value was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $4.10, exercise price of $4.00, term of 3 years, volatility of 138.0%, risk-free rate of 4.2%, and expected dividend rate of 0.0%). The fair value of the warrants on the grant date was $1.3 million and was recorded within additional paid-in capital as of March 31, 2024. Upon termination of the License Agreement on June 21, 2024, the offsetting amount recorded within additional paid-in capital as an unfunded stock subscription receivable was expensed to research and development.

Anson Warrants – Liability

The Anson Warrants, originally issued in the Anson Purchase Agreement, are recognized as derivative liabilities in accordance with ASC 815. The Company concluded liability classification was appropriate as certain settlement features included in the Anson Warrants are not indexed to the Company's own stock, and therefore preclude equity classification. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercise or expiration, and any change in fair value is recognized in the Company’s condensed consolidated statements of operations. The Anson Warrants are measured at fair value using a Black-Scholes model. Warrant liabilities are classified as current liabilities on the Company's condensed consolidated balance sheets. On August 14, 2024, in conjunction with the issuance of the First Tranche Notes, the Company issued warrants to purchase up to 1,349,305 shares of the Common Stock which were classified as a liability. The warrants have an exercise price of $2.4168 per share, subject to adjustment or other settlement provisions, and have a contractual term of five years expiring on August 14, 2029. The measurement of fair value of the Anson Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $1.86, exercise price of $2.42, term of five years, volatility of 122%, and risk-free rate of 3.67%, and expected dividend rate of 0%). The grant date fair value of these Anson Warrants was estimated to be $2.1 million on August 14, 2024.

On October 10, 2024, in conjunction with the issuance of the Second Tranche Notes, the Company issued warrants to purchase up to 1,846,128 shares of Common Stock which were classified as a liability. The warrants have an exercise price of $1.7664 per share, subject to adjustment or other settlement provisions, and have a contractual term of five years expiring on October 10, 2029. The measurement of fair value of the Investor Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $1.38, exercise price of $1.76, term of five years, volatility of 105%, and risk-free rate of 3.91%, and expected dividend rate of 0%). The grant date fair value of these Second Tranche Investor Warrants was estimated to be $1.9 million on October 10, 2024.

On January 28, 2025, in conjunction with the issuance of the Third Tranche Notes, the Company issued warrants to purchase up to 862,699 shares of Common Stock which were classified as a liability (See Note 14). The warrants had an initial exercise price of $3.78 per share, subject to adjustment or other settlement provisions, and have a contractual term of five years expiring on January 28, 2030. The measurement of fair value of the Investor Warrants was determined using a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $3.55, exercise price of $3.78, term of five years, volatility of 113%, risk-free rate of 4.33%, and expected dividend rate of 0%). The grant date fair value of these Third Tranche Investor Warrants was estimated to be $2.5 million on January 28, 2025.

In connection with the Second RD Purchase Agreement, and pursuant to the full ratchet anti-dilution provisions contained in the Anson financing agreements, the exercise price of all outstanding Common Stock purchase warrants issued on August 14, 2024, October 10, 2024, January 28, 2025, and January 29, 2025 (collectively, the “Anson Warrants”) were each adjusted to $1.65 per share. In addition, under the full ratchet provision of the warrants’ anti-dilution provision, the number of shares underlying the Anson Warrants was increased by an aggregate of 1,870,960 shares of common stock. The effect of the full ratchet trigger was $5.7 million and is reflected as part of the change in fair value of warrant liabilities on the statement of operations.

The holders of Anson Notes and Anson Warrants, in accordance with the an agreement entered into with Anson on September 30, 2025, agreed to, among other things, i) certain trading volume limitations, and ii) a partial exercise of previously issued Anson Warrants for cash. Specifically, if the closing stock price of the Company’s common stock as reported on the Principal Market (as defined in the August 2024 Purchase Agreement) is below $3.25 on any trading day, Anson may not sell, dispose of, or otherwise transfer, in the aggregate, more than 12.5% of the composite daily trading volume of the Company’s common stock on that trading day. In accordance with the agreement,

1,870,960 shares of underlying Anson Warrants, which were issued with the original convertible notes, were exercised on September 30, 2025, for cash proceeds of $3.1 million. The fair value of the exercised Anson Warrants liabilities was determined to be $5.4 million as of the exercise date, resulting in a gain of $5.4 million, recorded as gain in exercise of warrant liabilities and representing the difference between the fair value of the exercised Anson Warrants and the cash proceeds received. Because the exercise proceeds were received subsequent to September 30, 2025, the Company recorded a subscription receivable asset of $3.1 million as of September 30, 2025. The gain was recognized within other (income) expense for the three and nine months ended September 30, 2025.

RD Warrants – Liabilities

As discussed above, on January 29, 2025, in conjunction with the issuance of the First RD Shares, the Company issued the First RD Warrants to purchase up to 1,215,278 shares of Common Stock which were classified as a liability. The First RD Warrants have an exercise price of $2.88 per share and have a contractual term of five years expiring on January 29, 2030. The measurement of fair value of the First RD Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $2.07, exercise price of $2.88, term of five years, volatility of 115.8%, and risk-free rate of 4.00%). The grant date fair value of these First RD Warrants was estimated to be $3.983 million on January 29, 2025. As the fair value of the liabilities exceeded the net proceeds received of $3.255 million, the Company recognized the excess of the fair value over the net proceeds received of $3.255 million as a loss upon issuance of the First Registered Direct Offering of $0.7 million which is included in other expense (income) in the condensed consolidated statement of operations for the nine months ended September 30, 2025.

Consideration Warrants – Liability

As discussed above, on March 20, 2025, in conjunction with the issuance of the Consideration Shares, the Company issued Consideration Warrants to purchase up to 303,819 shares of Common Stock which were classified as a liability. The Consideration Warrants have an exercise price of $2.88 per share and have a contractual term of five years expiring on March 20, 2030.

The measurement of fair value of the Consideration Warrants were determined utilizing a Black-Scholes model considering all relevant assumptions current at the date of issuance (i.e., share price of $2.07, exercise price of $2.88, term of five years, volatility of 115.8%, and risk-free rate of 4.00%). The grant date fair value of these Consideration Warrants was estimated to be $0.6 million on March 20, 2025.

As of September 30, 2025, the aggregate fair value of all liability classified warrants, which include Substitute Warrants, Assumed Private Placement Warrants, Anson Warrants, First RD Warrants and Consideration Warrants, was $15.9 million. The Company recognized a loss on the change in fair value of the liability classified warrants for the three months ended September 30, 2025 of approximately $5.0 million, and a loss of approximately $8.5 million on the change in fair value of the liability classified warrants for the nine months ended September 30, 2025. In addition, the Company recognized a gain of $5.4 million upon the exercise of Anson Warrants, representing the difference between the fair value of the exercised warrant liabilities and the cash proceeds received. Refer to Note 14 for discussion of the fair value measurement of the Company’s warrant liabilities.

The following table provides the activity for all warrants for the respective periods.

								Aggregate
				*Weighted*		*Weighted*		*Intrinsic*
				*Average*		*Average*		*Value*
	Total Warrants			Remaining Term		Exercise Price		(in thousands)
Outstanding as of December 31, 2023		3,321,499			3.91	$	23.01	$	180
Issued		3,948,484			4.71		2.04		—
Expired		(96,417	)		—		—		—
Outstanding as of December 31, 2024		7,173,766			3.77	$	17.20	$	80
Issued		4,252,758			5.00		1.78		—
Exercised		(1,870,962	)		5.00		1.65		—
Expired		(107,596	)		—		—		—
Outstanding as of September 30, 2025		9,447,966			3.39	$	7.98	$	821

The entire disclosure for equity.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Note 8 - Accrued and Other Current Liabilities

9 Months Ended

Sep. 30, 2025

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

Note 8. Accrued and Other Current Liabilities

Accrued and other current liabilities consisted of the following at the dates indicated (in thousands):

	September 30, 2025		December 31, 2024
	(Unaudited)
Accrued and other current liabilities:
Refund liability (see Note 9)	$	4,715	$	4,715
Professional services		3,949		3,732
Employee costs		420		577
Accrued research and development expense		502		655
Accrued Dura acquisition cost due post-closing		191		-
Other accrued expense		98		470
Total accrued and other current liabilities	$	9,875	$	10,149

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
ASSETS
Cash and cash equivalents	$ 7,184	$ 1,443
Accounts receivable, net	239	0
Prepaid expense and other current assets	1,437	1,859
Subscription receivable	3,087	0
Total current assets	11,947	3,302
Other assets	243	340
Furniture and equipment, net	69	9
Right-of-use assets, net	350
Intangible assets, net	1,777	0
Goodwill	610	0
Total assets	14,996	3,651
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Accounts payable	4,257	4,130
Accrued and other current liabilities	9,875	10,149
Accrued clinical site costs	351	379
Convertible note payable and accrued interest, current	9,909	1,246
Insurance loan payable	152	320
Warrant liabilities	15,860	5,639
Total current liabilities	40,593	21,863
Convertible note payable and accrued interest, long term	0	5,011
Total liabilities	40,751	26,874
Commitments and Contingencies (Note 11)
Common Stock, $0.001 par value, 500,000,000 shares authorized; 27,682,530 and 14,591,505 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively	28	15
Additional paid-in capital	281,473	255,035
Accumulated deficit	(307,256)	(278,273)
Total stockholders’ deficit	(25,755)	(23,223)
Total liabilities and stockholders' deficit	14,996	3,651
Nondesignated Preferred Stock [Member]
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Preferred stock	0	0
Series A Convertible Preferred Stock [Member]
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Preferred stock	0	0
Nonrelated Party [Member]
ASSETS
Right-of-use assets, net	107	0
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Lease liability, short term	87	0
Lease liability, noncurrent	15	0
Related Party [Member]
ASSETS
Right-of-use assets, net	243	0
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Accounts payable	300	100
Lease liability, short term	102	0
Lease liability, noncurrent	$ 143	$ 0

Note 15 - Segment Reporting (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2025 USD ($)
Number of Operating Segments	2
Number of Reportable Segments	2
Revenue from Contract with Customer, Including Assessed Tax	$ 242

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

Note 6 - Furniture and Equipment, Net - Furniture and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
PPE	$ 93	$ 29
Less: Accumulated Depreciation	(24)	(20)
Net	69	9
Medical Equipment [Member]
PPE	57	0
Computer Equipment [Member]
PPE	32	29
Furniture and Fixtures [Member]
PPE	$ 4	$ 0

Note 9 - Alvogen Licensing Agreement (Details Textual) - USD ($) $ in Thousands	1 Months Ended
	Jun. 30, 2024	Sep. 30, 2025	Dec. 31, 2024
Customer Refund Liability, Current		$ 4,715	$ 4,715
Alvogen Licensing Agreement [Member]
Customer Refund Liability, Current		$ 4,700
Stock Subscriptions Receivable, Write Off	$ 1,300

Note 17 - Business Acquisition - Acquired Intangible Assets (Details) - Dura Medical [Member] - USD ($) $ in Thousands	Sep. 08, 2025	Sep. 30, 2025
Fair values	$ 1,801
Less accumulated amortization	(24)
Net carry value	1,777	$ 1,777
2025		98
2026		390
2027		390
2028		329
2029		189
Thereafter		381
Total	1,777	$ 1,777
Trademarks and Trade Names [Member]
Fair values	$ 669
Weighted average useful life (Year)	8 years
Customer Relationships [Member]
Fair values	$ 605
Weighted average useful life (Year)	3 years
Noncompete Agreements [Member]
Fair values	$ 527
Weighted average useful life (Year)	5 years

Note 4 - Revenue - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Accounts receivable, gross	$ 349
Less: allowance for credit losses	(110)	$ 0
Accounts receivable, net	239
Commercial Insurance [Member]
Accounts receivable, gross	198
Medicare [Member]
Accounts receivable, gross	34
Self-Pay [Member]
Accounts receivable, gross	$ 117

Note 5 - Prepaid Expense and Other Current Assets

9 Months Ended

Sep. 30, 2025

Prepaid Expenses and Other Current Assets [Text Block]

Note 5. Prepaid Expense and Other Current Assets

Prepaid expense and other current assets consisted of the following at the dates indicated (in thousands):

	September 30, 2025		December 31, 2024
	(Unaudited)
Prepaid expense and other current assets:
Prepaid insurance	$	658	$	827
Prepaid clinical development costs		44		824
Other prepaid expense		335		208
Total prepaid expense and other current assets	$	1,437	$	1,859

Note 2 - Going Concern

9 Months Ended

Sep. 30, 2025

Substantial Doubt about Going Concern [Text Block]

Note 2. Going Concern

The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the ordinary course of business. Since inception, the Company has incurred recurring operating losses and negative cash flows from operations. For the nine months ended September 30, 2025, the Company reported a net loss of approximately $29.0 million, used cash in operations of approximately $10.4 million, had an accumulated deficit of approximately $307.3 million. As of September 30, 2025, the Company had cash and cash equivalents of $7.2 million and a working capital deficit of $28.6 million.

The Company generated initial patient service revenue of approximately $0.2 million during the quarter ended September 30, 2025, following the acquisition of Dura on September 8, 2025. Management expects to continue incurring operating losses through at least the remainder of 2025 as it integrates Dura and pursues additional acquisitions through its HOPE subsidiary. While management projects incremental revenue from clinical operations and, upon regulatory approval, from pharmaceutical product sales, these projections are subject to significant uncertainty, including successful completion of pending acquisitions and receipt of FDA approval for NRX-100 and NRX-101.

As of September 30, 2025, the Company had $7.2 million in cash and cash equivalents. On January 27, 2025, the Company entered into a securities purchase agreement (the “First RD Purchase Agreement”) with the investors for the sale by the Company of 1,215,278 shares (the “First RD Shares”) of Common Stock to the investors, at a purchase price of $2.88 per share, in a registered direct offering (the “First Registered Direct Offering”). The closing of the sales of these securities under the First RD Purchase Agreement occurred on or about January 29, 2025 (the “First RD Closing Date”), resulting in net proceeds to the Company of approximately $3.255 million after transaction costs. Concurrently with the sale of the First RD Shares, pursuant to the First RD Purchase Agreement the Company also sold to the investors unregistered Common Stock purchase warrants (the “First RD Warrants”) to purchase up to an aggregate of 1,215,278 shares of Common Stock (the “First RD Warrant Shares”), in a private placement. Subject to certain beneficial ownership limitations, the RD Warrants are immediately exercisable upon issuance at an exercise price equal to $2.88 per share of Common Stock, subject to adjustments as provided under the terms of the RD Warrants and are exercisable for five years from the First RD Closing Date.

Pursuant to the purchase agreement (the “Anson Purchase Agreement”) with Anson Investment Master Fund LP and Anson East Master Fund LP (collectively “Anson”), on January 28, 2025 (the “Third Closing Date”), the Company sold a total of $5.4 million in Notes (as defined below) subject to an original issue discount of 8% or $0.435 million less other issuance costs of $0.4 million noted below (the “Third Tranche Notes” and collectively with the First Tranche Notes and Second Tranche Notes, the (“Anson Notes”)), with an aggregate purchase price of approximately $5.0 million, and warrants to purchase up to 862,699 shares of Common Stock. The Company intends to use the net proceeds from these transactions for general corporate purposes, including the funding of certain capital expenditures (See Note 10 and 12).

On September 30, 2025, 1,870,960 shares underlying Anson Warrants were exercised for cash proceeds of $3.09 million. Because the exercise proceeds were received subsequent to September 30, 2025, the Company recorded a subscription receivable asset of $3.09 million as of September 30, 2025. The exercise proceeds of $3.09 million were received on October 1, 2025.

On April 17, 2025, the Company reinstated its at-the-market offering and increased the maximum aggregate offering amount and filed a prospectus supplement under the offering agreement for an aggregate of $20,000,000. During the three months ended September 30, 2025, the Company sold an aggregate of 1,350,788 shares of Common Stock for approximately $3.81 million, net of less than $0.1 million in offered costs. During the nine months ended September 30, 2025, the Company sold an aggregate of 1,749,866 shares of Common Stock for approximately $4.85 million, net of $0.1 million in offering costs. For more information regarding the Company’s at-the-market offering, please see Note 12, “Equity,” of these unaudited condensed consolidated quarterly financial statements.

The Company has secured operating capital that it anticipates as sufficient to fund its drug development operations through at least the second quarter of 2026 and to finance submission of FDA NDAs for NRX-100 and NRX-101. The Company additionally expects to continue to accrue revenue from clinical operations. The Company may pursue additional equity or debt financing or refinancing opportunities in 2025 and 2026 to fund ongoing clinical activities, to meet obligations under its current debt arrangements and for general corporate purposes. Such arrangements may take the form of loans, equity offerings, strategic agreements, licensing agreements, joint ventures, or other agreements. The sale of equity could result in additional dilution to the Company’s existing stockholders. The Company cannot make any assurances that additional financing will be available to it and, if available, on acceptable terms, or that it will be able to refinance its existing debt obligations which could negatively impact the Company’s business and operations and could also lead to a reduction in the Company’s operations. The Company will continue to carefully monitor the impact of its continuing operations on the Company’s working capital needs and debt repayment obligations. As such, the Company has concluded that substantial doubt exists regarding the Company’s ability to continue as a going concern for a period of at least twelve months from the date of issuance of these condensed consolidated financial statements. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the company be unable to continue as a going concern.

Note 17 - Business Acquisition - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Sep. 08, 2025	Dec. 31, 2024
Goodwill	$ 610		$ 0
Dura Medical [Member]
Cash and cash equivalents		$ 536
Accounts receivable		251
Prepaid expenses		23
Furniture and equipment		64
Goodwill		610
Total assets acquired		3,651
Accounts payable and accrued expenses		(26)
Accrued salaries and benefits		(117)
Total liabilities assumed		(496)
Net assets acquired		3,155
Dura Medical [Member] \| Customer Lists [Member]
Customer relationship		605
Dura Medical [Member] \| Trade Names [Member]
Customer relationship		669
Dura Medical [Member] \| Noncompete Agreements [Member]
Customer relationship		527
Dura Medical [Member] \| Nonrelated Party [Member]
Right-of-use asset		114
Operating lease liability		(109)
Dura Medical [Member] \| Related Party [Member]
Right-of-use asset		252
Operating lease liability		$ (244)

Note 14 - Fair Value Measurements

9 Months Ended

Sep. 30, 2025

Fair Value Disclosures [Text Block]

Note 14. Fair Value Measurements

Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the three and nine months ended September 30, 2025 and 2024. The carrying amount of accounts payable approximated fair value as they are short term in nature. The fair value of stock options and warrants issued for services, and warrants issued with the Convertible Notes are estimated based on the Black-Scholes model. The fair value of the convertible notes payable was estimated utilizing a Monte Carlo simulation.

Fair Value on a Recurring Basis

The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the money market account represents a Level 1 measurement. The estimated fair value of the warrant liabilities and convertible note payable represent Level 3 measurements. The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at September 30, 2025 and December 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value (in thousands):

Description	Level		September 30, 2025		December 31, 2024
			(Unaudited)
Assets:
Money Market Account		1	$	403	$	487

Liabilities:
Warrant liabilities (Note 12)		3	$	15,860	$	5,639
Convertible note payable and accrued interest, current (Note 10)		3	$	9,909	$	1,246
Convertible note payable and accrued interest, non-current (Note 10)		3	$	—	$	5,011

Convertible Note Payable - Anson

The significant inputs used in the Monte Carlo simulation to measure the Anson Note liability that is categorized within Level 3 of the fair value hierarchy are as follows:

	September 30,
	2025
Stock price on valuation date	$	3.30
Conversion price	$	1.65
Time to expiration		0.50
Cost of debt		15.50	%
Equity volatility		71.2	%
Risk-free rate		3.83	%
Probability of credit default prior to maturity		1	%

The following table sets forth a summary of the changes in the fair value of the Anson Note categorized within Level 3 of the fair value hierarchy (in thousands):

Fair value of Anson Notes as of December 31, 2024	$	6,257
Fair value of Anson III Note at issuance		2,522
Conversion and repayments of principal and interest (shares)		(1,347	)
Fair value adjustment through earnings		965
Fair value of Anson Notes as of March 31, 2025		8,397
Conversion and repayments of principal and interest (shares)		(4,108	)
Fair value adjustment through earnings		5,565
Fair value of Anson Notes as of June 30, 2025		9,854
Conversion and repayments of principal and interest (shares)		(1,447	)
Fair value adjustment through earnings		1,502
Fair value of Anson Notes as of September 30, 2025	$	9,909

Convertible note payable - current portion as of September 30, 2025	$	9,909
Convertible note payable, net of current portion as of September 30, 2025	$	—

Warrant Liabilities

The Company utilizes a Black-Scholes model approach to value its liability-classified warrants at each reporting period, with changes in fair value recognized in the condensed consolidated statements of operations. The estimated fair value of the warrant liabilities is determined using Level 3 inputs. There were no transfers between levels within the fair value hierarchy during the periods presented. Inherent in a Black Scholes options pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its Common Stock based on historical volatility that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.

The weighted-average significant inputs used in the Black-Scholes model to measure the warrant liabilities that are categorized within Level 3 of the fair value hierarchy are as follows:

	September 30, 2025					December 31, 2024
Stock price on valuation date	$	3.30				$	2.20
Exercise price per share	$	1.65	–	11.50		$	2.08
Expected life		0.90	–	4.33			4.69
Volatility			124.31		%		111	%
Risk-free rate		3.61	–	3.68	%		4.37	%
Dividend yield			0.00		%		0.0	%
Fair value of warrants	$	0.02	–	2.89		$	1.76

A reconciliation of warrant liabilities is included below (in thousands):

Balance as of December 31, 2023	$	17
Loss upon re-measurement		9
Balance as of March 31, 2024		26
Gain upon re-measurement		(18	)
Balance as of June 30, 2024	$	8
Initial recognition of issuance of warrants		2,059
Gain upon re-measurement		(165	)
Balance as of September 30, 2024	$	1,902

Balance as of December 31, 2024	$	5,639
Initial recognition of issuance of warrants		7,109
Change in fair value of warrant liabilities		(2,896	)
Balance as of March 31, 2025	$	9,852
Change in fair value of warrant liabilities		6,414
Balance as of June 30, 2025	$	16,266
Change in fair value of warrant liabilities		4,963
Fair Value of Anson warrants exercised		(5,369	)
Balance as of September 30, 2025	$	15,860

Fair Value on a Nonrecurring Basis

Assets and liabilities that are measured at fair value on a nonrecurring basis relate primarily to tangible property and equipment, goodwill and other intangible assets, which are remeasured when the derived fair value is below carrying value in the consolidated balance sheets. For these assets, the Company does not periodically adjust carrying value to fair value except in the event of impairment. If it is determined that impairment has occurred, the carrying value of the asset is reduced to fair value and the difference is included in impairments and other charges, net in the consolidated statements of operations.

Assets that are measured at fair value and classified as level 3 on a non-recurring basis are as follows (in thousands):

Description	September 8, 2025
Trade name	$	669
Customer relationships	$	605
Non-compete agreements	$	527
Goodwill	$	610

All these assets were measured at the acquisition dates in conjunction with the Dura acquisition.

The significant unobservable inputs used in our level 3 fair value measurements during the nine months ended September 30, 2025 are as follows:

Areas	Valuation Techniques	Unobservable Inputs	Range (Weighted Average)
Trade name	Relief-from-Royalty Method	Royality Rate		5	%
		Revenue Growth Rate	10% average through FY2030, 8% thereafter
		Discount rate		25	%
		Income tax rate		26.5	%
		Economic useful life	8 yrs
Customer relationship	Multi-Period Excess Earnings Method (MPEEM)	Royalty rate		5	%
		Revenue Growth Rates	10% average through FY2030, 8% thereafter
		Expense Growth Rates		3	%
		Contributory Assets’ Charges as % from revenue		0.2 – 0.7	%
		Business development expense for new customers	4		%
		Distributor EBITA margin for customer relationships		4	%
		Discount rate		27	%
		Income tax rate		26.5	%
		Economic useful life	3 yrs
Non-compete agreements	With-and-without method	Replacement cost growth rate		3	%
		Cap Ex Rates		1	%
		Contributory Assets Rates		40	%
		After tax rate of return		40	%
		Useful life	7 yrs

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

Note 4 - Revenue (Details Textual) - USD ($) $ in Thousands	9 Months Ended
Note 4 - Revenue (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2025	Sep. 30, 2024
Accounts Receivable, Credit Loss Expense (Reversal)	$ (3)	$ 10

Note 4 - Revenue - Allowance for Credit Loss (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Beginning balance as of December 31, 2024	$ 0
Acquisition of Dura (September 8, 2025)	113
Provision (recovery) for expected credit losses	(3)	$ 10
Write-offs, net of recoveries	0
Ending Balance as of September 30, 2025	$ 110

Note 15 - Segment Reporting - Reconciliation of Loss From Operations to Total Loss (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024
Income (loss) from operations	$ (4,024)			$ (3,022)			$ (11,600)	$ (16,070)
Interest income	(2)			(6)			(8)	(40)
Interest expense	0			0			0	230
Change in fair value of convertible notes payable	1,502			(1,355)			8,032	(1,014)
Fair Value Adjustment of Warrants	4,963	$ 8,500		(165)			8,481	(174)
Loss on convertible note conversions	772			127			4,239	127
Gain on exercise of warrant liabilities	(5,369)			0			(5,369)	0
Net Income (Loss) Attributable to Parent	(5,890)	$ (17,581)	$ (5,512)	(1,623)	$ (7,897)	$ (6,528)	(28,982)	(16,048)
Loss on issuance of registered direct Common Stock							730	0
Loss on consideration shares and warrants	0			0			1,277	0
Convertible note default penalty	0			0			0	849
Operating Segments [Member]
Income (loss) from operations	(4,024)			(3,022)			(11,600)	(16,070)
Interest income	(2)			(6)			(8)	(40)
Interest expense	0			0			0	230
Change in fair value of convertible notes payable	1,502			(1,355)			8,302	(1,014)
Fair Value Adjustment of Warrants	4,963			(165)			8,481	(174)
Loss on convertible note conversions	772			127			4,239	127
Gain on exercise of warrant liabilities	(5,369)			0			(5,369)	0
Net Income (Loss) Attributable to Parent	(5,890)			$ (1,623)			(28,982)	(16,048)
Loss on issuance of registered direct Common Stock							730	0
Loss on consideration shares and warrants							1,277	0
Convertible note default penalty							0	$ 849
Operating Segments [Member] \| NRx Segment [Member]
Income (loss) from operations	(4,039)						(11,616)
Interest income	(1)						(7)
Interest expense	0						0
Change in fair value of convertible notes payable	1,502						8,032
Fair Value Adjustment of Warrants	4,963						8,481
Loss on convertible note conversions	772						4,239
Gain on exercise of warrant liabilities	(5,369)						(5,369)
Net Income (Loss) Attributable to Parent	(5,906)						(28,999)
Loss on issuance of registered direct Common Stock							730
Loss on consideration shares and warrants							1,277
Convertible note default penalty							0
Operating Segments [Member] \| Dura Segment [Member]
Income (loss) from operations	15						15
Interest income	(1)						(1)
Interest expense	0						0
Change in fair value of convertible notes payable	0						0
Fair Value Adjustment of Warrants	0						0
Loss on convertible note conversions	0						0
Gain on exercise of warrant liabilities	0						0
Net Income (Loss) Attributable to Parent	$ 16						16
Loss on issuance of registered direct Common Stock							0
Loss on consideration shares and warrants							0
Convertible note default penalty							$ 0

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (5,890)	$ (5,512)	$ (1,623)	$ (6,528)	$ (28,982)	$ (16,048)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	26		2		28	4
Amortization of operating right of use assets					15	0
Stock-based compensation					147	443
Common Stock issued in exchange for services					600	37
Change in fair value of warrant liabilities	4,963		(165)		8,481	(174)
Change in fair value of convertible promissory notes					8,032	(1,011)
Loss on convertible note conversions	772		127		4,239	127
Gain on exercise of warrant liabilities	(5,369)		0		(5,369)	0
Loss on issuance of registered direct Common Stock					730	0
Loss on consideration shares and warrants	0		0		1,277	0
Expense for debt issuance costs due to fair value election on Anson Notes					350	521
Warrant issuance costs related to Alvogen termination					0	1,336
Convertible note default penalty	0		0		0	849
Changes in operating assets and liabilities:
Prepaid expense and other assets					414	(100)
Account receivable					12	0
Accounts payable					100	4,949
Insurance loan payable					0	634
Operating lease liabilities					(63)	0
Accrued expense and other liabilities					(412)	(106)
Net cash used in operating activities					(10,399)	(8,539)
CASH FLOWS FROM INVESTING ACTIVITIES
Business acquisition, net of cash acquired					(2,561)	0
Net cash used in investing activities					(2,561)	0
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of convertible note					0	(4,800)
Repayment of insurance note					(394)	0
Expense for debt issuance costs due to fair value election on Anson Notes					(350)	(521)
Proceeds from issuance of insurance loan					227	0
Proceeds from Anson convertible note, net					5,000	2,941
Proceeds from liability classified warrants					0	2,059
ATM offering, net of offering costs					4,751	0
Proceeds from issuance of Common Stock and warrants issued in private placement, net of issuance costs					0	1,027
Net cash provided by financing activities					18,701	5,590
Net increase (decrease) in cash and cash equivalents					5,741	(2,949)
Cash and cash equivalents at beginning of period		$ 1,443		$ 4,595	1,443	4,595	$ 4,595
Cash and cash equivalents at end of period	$ 7,184		$ 1,646		7,184	1,646	$ 1,443
Supplemental disclosure of cash flow information:
Cash paid for interest					374	374
Cash paid for taxes					0	0
Non-cash investing and financing activities:
Issuance of Common Stock warrants as offering costs					0	188
Exercise of the warrants for subscription receivable					3,087	0
Amortization of deferred offering costs to additional paid-in capital					120	0
Conversion of Series A Preferred Stock to Common Stock [Member]
Non-cash investing and financing activities:
Conversion of Series A preferred stock into Common Stock					0	3
Conversion of Principal and Interest Into Common Stock [Member]
Non-cash investing and financing activities:
Issuance of Common Stock as principal and interest repayment for convertible notes					11,142	1,102
Consideration Warrants [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of Common Stock and warrants, net of issuance costs					9,468	0
Warrants Other Than Consideration Warrants [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of Common Stock and warrants, net of issuance costs					$ 0	$ 4,884

Note 5 - Prepaid Expense and Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2025

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

	September 30, 2025		December 31, 2024
	(Unaudited)
Prepaid expense and other current assets:
Prepaid insurance	$	658	$	827
Prepaid clinical development costs		44		824
Other prepaid expense		335		208
Total prepaid expense and other current assets	$	1,437	$	1,859

Note 12 - Equity - Schedule of Warrants (Details) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2025 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares
Outstanding, balance (in shares)	7,173,766	3,321,499
Outstanding, weighted average remaining contractual term (Year)	3 years 4 months 20 days	3 years 9 months 7 days	3 years 10 months 28 days
Outstanding, weighted average exercise price (in dollars per share) \| $ / shares	$ 17.2	$ 23.01
Outstanding, aggregate intrinsic value \| $	$ 821	$ 80	$ 180
Issued (in shares)	4,252,758	3,948,484
Issued, weighted average remaining term (Year)	5 years	4 years 8 months 15 days
Issued, weighted average exercise price (in dollars per share) \| $ / shares	$ 1.78	$ 2.04
Expired (in shares)	(107,596)	(96,417)
Exercised (in shares)	(1,870,962)
Exercised, weighted average remaining term (Year)	5 years
Exercised, weighted average exercise price (in dollars per share) \| $ / shares	$ 1.65
Outstanding, balance (in shares)	9,447,966	7,173,766	3,321,499
Outstanding, weighted average exercise price (in dollars per share) \| $ / shares	$ 7.98	$ 17.2	$ 23.01

Note 11 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended
	Apr. 16, 2021	Sep. 30, 2025	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Apr. 16, 2022
Research and Development Expense		$ 1,429	$ 611		$ 3,219	$ 5,163
Operating Lease, Expense		18			18
Maximum [Member] \| Lease Contractual Term, Office Space, Rental [Member]
Operating Lease, Expense		$ 100	100		$ 100	100
Sarah Herzog Memorial Hospital License Agreement [Member]
License Agreements, Milestone Payments, Conditional Reduction Percentage		25.00%			25.00%
License Agreement, Cumulative Payments		$ 500			$ 500
License Agreement, Milestone Payment		0	0		200	0
Payments for Royalties		$ 0		$ 0	0	0
Payment for License Agreement, Maintenance Fee	$ 100,000				$ 0	0
License Agreement, Maintenance Fee							$ 150,000
Sarah Herzog Memorial Hospital License Agreement [Member] \| Maximum [Member]
Royalty Percentage		8.50%			8.50%
Sarah Herzog Memorial Hospital License Agreement [Member] \| Products Covered By Licensed Patents [Member]
Royalty Percentage		1.00%			1.00%
Sarah Herzog Memorial Hospital License Agreement [Member] \| Products Covered by Valid Claims [Member]
Royalty Percentage		2.50%			2.50%
Exclusive License Agreement [Member] \| Patent License [Member]
Research and Development Expense		$ 0	$ 0		$ 0	$ 0

Note 13 - Stock-based Compensation

9 Months Ended

Sep. 30, 2025

Share-Based Payment Arrangement [Text Block]

Note 13. Stock-Based Compensation

2016 Omnibus Incentive Plan

Prior to the Merger, the Company maintained its 2016 Omnibus Incentive Plan (the “2016 Plan”), under which NeuroRx granted incentive stock options, restricted stock awards, other stock-based awards, or other cash-based awards to employees, directors, and non-employee consultants. The maximum aggregate shares of Common Stock that were subject to awards and issuable under the 2016 Plan was 347,200.

In connection with the Merger, each option of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time (whether vested or unvested) was assumed by BRPA and converted into an option to acquire an adjusted number of shares of Common Stock at an adjusted exercise price per share, based on the Exchange Ratio (of 0.316:1).

Upon the closing of the Merger, the outstanding and unexercised NeuroRx stock options became options to purchase an aggregate 289,542 shares of Common Stock at an average exercise price of $51.00 per share.

2021 Omnibus Incentive Plan

As of September 30, 2025, 1,050,809 shares of Common Stock are authorized for issuance pursuant to awards under the Company’s 2021 Omnibus Incentive Plan (the “2021 Plan”). As of January 1, 2025, 95,528 shares were added to the 2021 Plan under an evergreen feature that automatically increases the reserve with additional shares of Common Stock for future issuance under the Incentive Plan each calendar year, beginning January 1, 2022 and ending on and including January 1, 2031, equal to the lesser of (A) 1% of the shares of Common Stock outstanding on the final day of the immediately preceding calendar year or (B) a smaller number of shares determined by the Board. On December 28, 2023, the first amendment to the 2021 Plan was executed which increased the maximum number of shares (i) available for issuance under the Plan by an additional 200,000 shares, and (ii) that may be delivered pursuant to the exercise of Incentive Stock Options granted under the 2021 Plan to be equal to 100% of the Share Pool. As of September 30, 2025, an aggregate 1,117,099 shares of Common Stock have been awarded net of forfeitures, and 18,085 shares of Common Stock remain available for issuance under the 2021 Plan. The 2021 Plan permits the granting of incentive stock options, restricted stock awards, other stock-based awards or other cash-based awards to employees, directors, and non-employee consultants.

Option Awards

The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company is a public company and has limited company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the limited company-specific historical volatility and implied volatility. The expected term of the Company’s stock options for employees has been determined utilizing the “simplified” method for awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. Additionally, certain options granted contain terms that require all unvested options to immediately vest a) upon the approval of an NDA by the FDA for NRX‑101, or b) immediately preceding a change in control of the Company, whichever occurs first.

On February 7, 2025, the Company issued 50,000 stock options. These shares have a vesting term of three years, an expiration date of ten years from the grant date and were valued at approximately $0.1 million as of the grant date.

On April 9, 2025, the Company issued 497,000 stock options. These shares have a vesting term of three years, an expiration date of ten years from the grant date and were valued at approximately $0.6 million as of the grant date.

The stock options granted during the nine months were valued utilizing the Black-Scholes options pricing model with the following inputs: $1.78-2.94 of stock price, 3.91%-4.31% risk-free rate, 127%-126.76% volatility, 0% dividend rate, and the expected term of 3 years.

The following table summarizes the Company’s employee and non-employee stock option activity under the 2021 Plan for the following periods:

						Weighted
						average
				*Weighted*		*remaining*		*Aggregate*
				*average*		*contractual*		*intrinsic*
	*Number of*			*exercise*		*life (in*		*value (in*
	*shares*			*price*		*years)*		*thousands)*
Outstanding as of December 31, 2023		264,983		$	18.30		7.7	$	75
Options granted		—			—		—		—
Forfeited/Expire		(143,150	)		—		—		—
Outstanding as of December 31, 2024		121,833			22.36		7.0		—
Options granted		547,000			1.84		10.0
Forfeited/Expire		(5,380	)		—		—		—
Outstanding as of September 30, 2025		663,453			5.54		9.0		—
Options vested and exercisable as of September 30, 2025		119,281		$	22.52		6.3	$	—

Stock-based compensation expense related to stock options was less than $0.1 million and $0.1 million for the three months ended September 30, 2025 and 2024, respectively. Stock-based compensation expense related to stock options was approximately $0.15 million and approximately $0.1 million for the nine months ended September 30, 2025 and 2024, respectively.

At September 30, 2025, the total unrecognized compensation related to unvested employee and non-employee stock option awards granted was $0.6 million, which the Company expects to recognize over a weighted-average period of approximately 2.49 years.

Restricted Stock Awards

The following table presents the Company’s Restricted Stock Activity:

				Weighted
				Average Grant
				Date Fair
	Awards			Value
Balance as of December 31, 2023 (unvested)		124,166		$	5.20
Granted		—
Vested		(90,833	)	$	4.64
Forfeited		(33,333	)	$	5.20
Balance as of December 31, 2024 (unvested)		—			—
Granted		—		$	—
Vested		—		$	—
Forfeited		—		$	—
Balance as of September 30, 2025 (unvested)		—			—

On July 12, 2022, the board of directors (the “Board”) granted an award of 100,000 restricted shares of the Company as an inducement to the newly appointed chief executive officer, pursuant to a separate Restricted Stock Award Agreement (the “RSA”). The Restricted Stock vested in approximately equal installments over three (3) years from the grant date, subject to continued service through the applicable vesting date.

On December 28, 2023, the Company granted 57,500 RSAs to a consultant for services provided. The RSAs vested after six months from the grant date. The shares were valued on the grant date based on the quoted price of $4.60 or approximately $0.3 million, which was amortized over the vesting term.

Stock-based compensation expense related to RSAs was $0 and less than $0.1 million for the three months ended September 30, 2025 and 2024, respectively. Stock-based compensation expense related to RSAs was $0 and less than $0.1 million for the nine months ended September 30, 2025 and 2024, respectively.

In October 2024, the Company's chief executive officer announced his resignation and as a result, all unvested RSAs were forfeited. Accordingly, the Company does not expect to recognize any further stock-based compensation expense for the balance of unvested RSAs as of December 31, 2024.

The following table summarizes the Company’s recognition of stock-based compensation for the following periods (in thousands):

	Three months ended September 30,				Nine months ended September 30,
	2025		2024		2025		2024
	(Unaudited)
Stock-based compensation expense
General and administrative	$	56	$	82	$	123	$	365
Research and development		12		22		24		78
Total stock-based compensation expense	$	68	$	97	$	147	$	339

Note 10 - Debt (Details Textual)										3 Months Ended				9 Months Ended		12 Months Ended
Note 10 - Debt (Details Textual)	Sep. 30, 2025 USD ($) $ / shares shares	Mar. 20, 2025 USD ($) $ / shares shares	Jan. 28, 2025 USD ($) $ / shares shares	Jan. 20, 2025 USD ($)	Oct. 10, 2024 USD ($) $ / shares shares	Aug. 15, 2024 USD ($)	Aug. 14, 2024 USD ($) $ / shares shares	Aug. 12, 2024 USD ($)	Nov. 04, 2022 USD ($)	Sep. 30, 2025 USD ($) $ / shares shares	Jun. 30, 2025 USD ($) shares	Mar. 31, 2025 USD ($) shares	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($) $ / shares shares	Sep. 30, 2024 USD ($)	Dec. 31, 2024 USD ($) shares
Debt Issuance Costs														$ 350,000	$ 521,000
Proceeds from Convertible Debt														5,000,000	2,941,000
Gain (Loss) on Convertible Debt Redemption										$ (772,000)			$ (127,000)	$ (4,239,000)	$ (127,000)
Consent and Waiver Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares) \| shares		303,819
Anson Warrants [Member]
Class of Warrant or Right, Securities Called by Warrants or Rights, Percentage of Principal Divided by VWAP								50.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares	1,870,960									1,870,960				1,870,960
Warrants and Rights Outstanding							$ 2,100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 1,870,960									$ 1,870,960				$ 1,870,960
Class of Warrant or Right, Stock Price Trigger (in dollars per share) \| $ / shares	$ 3.25									$ 3.25				$ 3.25
Class of Warrant or Right, Percentage Trading Volume Threshold If Triggered	12.50%									12.50%				12.50%
Proceeds from Warrant Exercises	$ 3,090,000.00
Stock Issued During Period, Shares, Warrants Exercised (in shares) \| shares	1,870,960
Anson Warrants Tranche One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares							1,349,305
Warrants and Rights Outstanding							$ 2,100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares							$ 2.4168
Third Tranche Notes, Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares			862,699				862,699,000,000
Consideration Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares		303,819
Class of Warrant or Right Issued in Period (in shares) \| shares		303,819
Warrants and Rights Outstanding		$ 600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares		$ 2.88
Anson Warrants Tranche Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares					1,846,128
Warrants and Rights Outstanding					$ 1,900,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares					$ 1.7664
Anson Warrants, Tranche Three [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares			862,699
Warrants and Rights Outstanding			$ 2,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares			$ 3.78
Streetervile Complaint [Member]
Litigation Settlement, Payment Installment One								$ 2,500,000
Litigation Settlement, Payment Installment Two								3,100,000
Streeterville Convertible Note [Member]
Debt Instrument, Face Amount									$ 11,000,000
Debt Instrument, Term (Month)									825 months
Long-Term Debt, Gross	$ 0									$ 0				$ 0		$ 0
Repayments of Debt						$ 2,500,000
Anson Convertible Notes [Member]
Debt Instrument, Face Amount								16,300,000
Long-Term Debt, Gross								$ 15,000,000
Debt Instrument, Number of Tranches								3
Placement Agent Fee, Percent of Gross Proceeds								7.00%
Long-Term Debt, Principal Only	5,400,000									5,400,000				5,400,000
Interest Payable	$ 300,000									$ 300,000				$ 300,000
Anson Convertible Notes [Member] \| Conversion of Principal and Interest Into Common Stock [Member]
Debt Conversion, Original Debt, Amount																$ 4,200,000
Debt Conversion, Converted Instrument, Shares Issued (in shares) \| shares																3,676,796
Gain (Loss) on Convertible Debt Redemption																$ (1,300,000)
Anson First Tranche Notes [Member]
Debt Instrument, Face Amount							$ 5,400,000
Debt Instrument, Term (Month)							15 months
Long-Term Debt, Gross							$ 2,900,000
Debt Instrument, Original Issuance Discount							8.00%
Debt Instrument, Unamortized Discount							$ 435,000
Debt Issuance Costs							521,000
Proceeds from Debt, Net of Issuance Costs							$ 4,500,000
Debt Instrument, Interest Rate, Stated Percentage							6.00%
Debt Instrument, Interest Rate in Event of Default							10.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares							$ 2.4168
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger							92.00%
Anson First Tranche Notes [Member] \| Conversion of Principal and Interest Into Common Stock [Member]
Debt Conversion, Original Debt, Amount												$ 1,300,000				$ 4,200,000
Debt Conversion, Converted Instrument, Shares Issued (in shares) \| shares												1,004,055				3,676,796
Gain (Loss) on Convertible Debt Redemption												$ (1,600,000)				$ (1,300,000)
Anson First Tranche Notes [Member] \| Conversion of Principal Into Common Stock [Member]
Debt Conversion, Original Debt, Amount												1,300,000
Anson First Tranche Notes [Member] \| Conversion of Accrued Interest Into Common Stock [Member]
Debt Conversion, Original Debt, Amount												$ 100,000
Anson First Tranche Notes [Member] \| Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares							$ 0.38
Anson Second Tranche Notes [Member]
Debt Instrument, Face Amount					$ 5,400,000
Long-Term Debt, Gross					$ 3,100,000
Placement Agent Fee, Percent of Gross Proceeds					7.00%
Debt Instrument, Original Issuance Discount					8.00%
Debt Instrument, Unamortized Discount					$ 435,000
Debt Issuance Costs					$ 375,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares					1,846,128
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares	$ 1.65				$ 1.7664					$ 1.65				$ 1.65
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger					92.00%
Proceeds from Convertible Debt					$ 5,000,000
Debt Issuance Costs, Gross					400,000
Debt Instrument, Interest Rate, Effective Percentage	172.00%									172.00%				172.00%
Streetervile Complaint [Member]
Payments for Legal Settlements					$ 3,100,000
Anson, Third Tranche Notes [Member]
Debt Instrument, Face Amount			$ 5,400,000
Long-Term Debt, Gross			$ 2,500,000
Placement Agent Fee, Percent of Gross Proceeds			7.00%
Debt Instrument, Original Issuance Discount			8.00%
Debt Instrument, Unamortized Discount			$ 435,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares			$ 3.78
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger			92.00%
Proceeds from Convertible Debt			$ 5,000,000
Debt Issuance Costs, Gross			$ 400,000
Debt Instrument, Convertible, Threshold Trading Days			7
Anson, Third Tranche Notes [Member] \| Conversion of Principal and Interest Into Common Stock [Member]
Debt Conversion, Original Debt, Amount		$ 100,000		$ 100,000						$ 1,400,000	$ 4,100,000
Debt Conversion, Converted Instrument, Shares Issued (in shares) \| shares		5,463								877,193	1,879,406	5,463
Gain (Loss) on Convertible Debt Redemption										$ (800,000)	$ (1,900,000)
Anson First and Third Tranche Notes [Member] \| Conversion of Principal and Interest Into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) \| shares												1,009,518
Gain (Loss) on Convertible Debt Redemption												$ (1,600,000)
Anson Second and Third Tranche Notes [Member]
Liabilities, Fair Value Adjustment										$ 800,000				$ 2,700,000

Note 14 - Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2025

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

Description	Level		September 30, 2025		December 31, 2024
			(Unaudited)
Assets:
Money Market Account		1	$	403	$	487

Liabilities:
Warrant liabilities (Note 12)		3	$	15,860	$	5,639
Convertible note payable and accrued interest, current (Note 10)		3	$	9,909	$	1,246
Convertible note payable and accrued interest, non-current (Note 10)		3	$	—	$	5,011

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

	September 30,
	2025
Stock price on valuation date	$	3.30
Conversion price	$	1.65
Time to expiration		0.50
Cost of debt		15.50	%
Equity volatility		71.2	%
Risk-free rate		3.83	%
Probability of credit default prior to maturity		1	%

	September 30, 2025					December 31, 2024
Stock price on valuation date	$	3.30				$	2.20
Exercise price per share	$	1.65	–	11.50		$	2.08
Expected life		0.90	–	4.33			4.69
Volatility			124.31		%		111	%
Risk-free rate		3.61	–	3.68	%		4.37	%
Dividend yield			0.00		%		0.0	%
Fair value of warrants	$	0.02	–	2.89		$	1.76

Areas	Valuation Techniques	Unobservable Inputs	Range (Weighted Average)
Trade name	Relief-from-Royalty Method	Royality Rate		5	%
		Revenue Growth Rate	10% average through FY2030, 8% thereafter
		Discount rate		25	%
		Income tax rate		26.5	%
		Economic useful life	8 yrs
Customer relationship	Multi-Period Excess Earnings Method (MPEEM)	Royalty rate		5	%
		Revenue Growth Rates	10% average through FY2030, 8% thereafter
		Expense Growth Rates		3	%
		Contributory Assets’ Charges as % from revenue		0.2 – 0.7	%
		Business development expense for new customers	4		%
		Distributor EBITA margin for customer relationships		4	%
		Discount rate		27	%
		Income tax rate		26.5	%
		Economic useful life	3 yrs
Non-compete agreements	With-and-without method	Replacement cost growth rate		3	%
		Cap Ex Rates		1	%
		Contributory Assets Rates		40	%
		After tax rate of return		40	%
		Useful life	7 yrs

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Fair value of Anson Notes as of December 31, 2024	$	6,257
Fair value of Anson III Note at issuance		2,522
Conversion and repayments of principal and interest (shares)		(1,347	)
Fair value adjustment through earnings		965
Fair value of Anson Notes as of March 31, 2025		8,397
Conversion and repayments of principal and interest (shares)		(4,108	)
Fair value adjustment through earnings		5,565
Fair value of Anson Notes as of June 30, 2025		9,854
Conversion and repayments of principal and interest (shares)		(1,447	)
Fair value adjustment through earnings		1,502
Fair value of Anson Notes as of September 30, 2025	$	9,909

Convertible note payable - current portion as of September 30, 2025	$	9,909
Convertible note payable, net of current portion as of September 30, 2025	$	—

Balance as of December 31, 2023	$	17
Loss upon re-measurement		9
Balance as of March 31, 2024		26
Gain upon re-measurement		(18	)
Balance as of June 30, 2024	$	8
Initial recognition of issuance of warrants		2,059
Gain upon re-measurement		(165	)
Balance as of September 30, 2024	$	1,902

Balance as of December 31, 2024	$	5,639
Initial recognition of issuance of warrants		7,109
Change in fair value of warrant liabilities		(2,896	)
Balance as of March 31, 2025	$	9,852
Change in fair value of warrant liabilities		6,414
Balance as of June 30, 2025	$	16,266
Change in fair value of warrant liabilities		4,963
Fair Value of Anson warrants exercised		(5,369	)
Balance as of September 30, 2025	$	15,860

Fair Value Measurements, Nonrecurring [Table Text Block]

Description	September 8, 2025
Trade name	$	669
Customer relationships	$	605
Non-compete agreements	$	527
Goodwill	$	610

Note 13 - Stock-based Compensation (Details Textual) $ / shares in Units, $ in Thousands						3 Months Ended		9 Months Ended		12 Months Ended
	Apr. 09, 2025 USD ($) shares	Feb. 07, 2025 USD ($) shares	Jan. 01, 2024 shares	Dec. 28, 2023 USD ($) $ / shares shares	Jul. 12, 2022 shares	Sep. 30, 2025 USD ($) $ / shares shares	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($) $ / shares shares	Sep. 30, 2024 USD ($)	Dec. 31, 2024 USD ($) $ / shares shares	Jul. 17, 2025 $ / shares	Jun. 30, 2025 $ / shares	Dec. 31, 2023 $ / shares shares	Jan. 01, 2022	May 24, 2021 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)						663,453		663,453		121,833			264,983
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) \| $ / shares						$ 5.54		$ 5.54		$ 22.36			$ 18.3
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)								547,000		0
Share Price (in dollars per share) \| $ / shares											$ 3
Share-Based Payment Arrangement, Expense \| $						$ 68	$ 97	$ 147	$ 339
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate								0.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	497,000	50,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	10 years	10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Fair Value \| $	$ 600	$ 100
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum								3.91%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum								4.31%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum								127.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum								126.76%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)								3 years
Share-Based Payment Arrangement, Expense \| $						100	100	$ 150	100
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount \| $						600		$ 600
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)								2 years 5 months 26 days
Share-Based Payment Arrangement, Option [Member] \| Minimum [Member]
Share Price (in dollars per share) \| $ / shares												$ 1.78
Share-Based Payment Arrangement, Option [Member] \| Maximum [Member]
Share Price (in dollars per share) \| $ / shares												$ 2.94
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)				57,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)				6 months
Share-Based Payment Arrangement, Expense \| $						$ 0	$ 100	$ 0	$ 100
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount \| $										$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)								0		0
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) \| $ / shares				$ 4.6
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value \| $				$ 300
Restricted Stock [Member] \| Chief Executive Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)					3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)					100,000
The 2016 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)						347,200		347,200
The 2016 Omnibus Incentive Plan [Member] \| Neuro Rx [Member]
Foreign Currency Exchange Rate, Remeasurement															0.316
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)															289,542
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share) \| $ / shares															$ 51
The 2021 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)						1,050,809		1,050,809
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)			95,528	200,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Percentage Increase in Authorized Shares														1.00%
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares)								1,117,099
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)						18,085		18,085

Note 14 - Fair Value Measurements - Schedule of Assets and Liabilities on A Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Fair Value, Inputs, Level 1 [Member]
Money Market Account	$ 403	$ 487
Fair Value, Inputs, Level 3 [Member]
Warrant liabilities (Note 12)	15,860	5,639
Fair Value, Inputs, Level 3 [Member] \| Convertible Notes Except Anson Note [Member]
Convertible note payable and accrued interest, current (Note 10)	9,909	1,246
Fair Value, Inputs, Level 3 [Member] \| Anson Convertible Notes [Member]
Convertible note payable and accrued interest, current (Note 10)	$ 0	$ 5,011

Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-10

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483444/210-20-55-22

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483444/210-20-55-21

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483444/210-20-55-20

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483444/210-20-55-15

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483444/210-20-55-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483466/210-20-50-3

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-3

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G)(Footnote 8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5A
-Subparagraph (SX 210.12-13A(Column E))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B

Note 12 - Equity (Tables)

9 Months Ended

Sep. 30, 2025

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

								Aggregate
				*Weighted*		*Weighted*		*Intrinsic*
				*Average*		*Average*		*Value*
	Total Warrants			Remaining Term		Exercise Price		(in thousands)
Outstanding as of December 31, 2023		3,321,499			3.91	$	23.01	$	180
Issued		3,948,484			4.71		2.04		—
Expired		(96,417	)		—		—		—
Outstanding as of December 31, 2024		7,173,766			3.77	$	17.20	$	80
Issued		4,252,758			5.00		1.78		—
Exercised		(1,870,962	)		5.00		1.65		—
Expired		(107,596	)		—		—		—
Outstanding as of September 30, 2025		9,447,966			3.39	$	7.98	$	821

Note 14 - Fair Value Measurements - Schedule of Nonrecurring Level 3 Fair Value Measurements (Details) - Fair Value, Inputs, Level 3 [Member] - Fair Value, Nonrecurring [Member]	Sep. 30, 2025 USD ($)
Goodwill	$ 610
Trade Names [Member]
Intangible assets, fair value	669
Customer Relationships [Member]
Intangible assets, fair value	605
Noncompete Agreements [Member]
Intangible assets, fair value	$ 527

Note 17 - Business Acquisition (Details Textual) - USD ($)		3 Months Ended						9 Months Ended
	Sep. 08, 2025	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Goodwill		$ 610,000						$ 610,000		$ 0
Revenue from Contract with Customer, Excluding Assessed Tax		242,000			$ 0			242,000	$ 0
Net Income (Loss) Attributable to Parent		(5,890,000)	$ (17,581,000)	$ (5,512,000)	(1,623,000)	$ (7,897,000)	$ (6,528,000)	(28,982,000)	(16,048,000)
Dura Medical [Member]
Business Combination, Consideration Transferred	$ 3,300,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred	100,000	100,000
Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount	$ 3,000,000
Business Combination, Excluded from Purchase Price, Contingent Consideration, Term (Year)	3 years
Business Combination, Acquisition-Related Cost, Expense								100,000
Amortization		24,000
Goodwill	$ 610,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles		$ 100,000			300,000			500,000	$ 900,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Finders Fees					$ 100,000
Revenue from Contract with Customer, Excluding Assessed Tax								242,000
Net Income (Loss) Attributable to Parent								$ 16,000
Dura Medical [Member] \| Class A Units [Member]
Business Combination, Excluded From Purchase Price, Issuance of Shares (in shares)	6,188

Note 7 - Leases - Balance Sheet Disclosures (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Total non-current lease assets	$ 350
Total lease liabilities	347
Nonrelated Party [Member]
Total non-current lease assets	107	$ 0
Operating lease liability, current	87	0
Operating lease liability, non current	15	0
Related Party [Member]
Total non-current lease assets	243	0
Operating lease liability, current	102	0
Operating lease liability, non current	$ 143	$ 0

Note 8 - Accrued and Other Current Liabilities (Tables)

9 Months Ended

Sep. 30, 2025

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

	September 30, 2025		December 31, 2024
	(Unaudited)
Accrued and other current liabilities:
Refund liability (see Note 9)	$	4,715	$	4,715
Professional services		3,949		3,732
Employee costs		420		577
Accrued research and development expense		502		655
Accrued Dura acquisition cost due post-closing		191		-
Other accrued expense		98		470
Total accrued and other current liabilities	$	9,875	$	10,149

Note 4 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Net patient service revenue	$ 242	$ 0	$ 242	$ 0
Commercial Insurance [Member]
Net patient service revenue	156		156
Medicare [Member]
Net patient service revenue	9		9
Self-Pay [Member]
Net patient service revenue	77		77
Procedures [Member]
Net patient service revenue	90		90
Therapy [Member]
Net patient service revenue	$ 152		$ 152

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4